82 results on '"Yuki Kataoka"'
Search Results
2. A case of gangrenous cystitis with bilateral hydronephrosis 10 years after radiotherapy
- Author
-
Mariko Oniwa, Yuki Kataoka, Midori Yamada, Takuya Miyagawa, Takuro Sunada, Hideyuki Konishi, Gen Suzuki, and Yoko Fujita
- Subjects
Internal Medicine ,Geriatrics and Gerontology ,Family Practice - Published
- 2023
3. Efficacy of acceptance and commitment therapy for people with type 2 diabetes: Systematic review and meta‐analysis
- Author
-
Hiromichi Matsuoka, Kazuhiro Yoshiuchi, Yoichi Ohtake, Tomokazu Hata, Akira Yamane, Jun Otonari, Yoshinobu Matsuda, Ryo Sakamoto, and Yuki Kataoka
- Subjects
medicine.medical_specialty ,Type 2 diabetes ,Endocrinology, Diabetes and Metabolism ,Acceptance and commitment therapy ,Diseases of the endocrine glands. Clinical endocrinology ,law.invention ,chemistry.chemical_compound ,Randomized controlled trial ,law ,Internal medicine ,Diabetes mellitus ,Surveys and Questionnaires ,Internal Medicine ,medicine ,Humans ,Glycated Hemoglobin ,business.industry ,General Medicine ,medicine.disease ,RC648-665 ,Confidence interval ,Clinical trial ,Self Care ,chemistry ,Diabetes Mellitus, Type 2 ,Meta-analysis ,Meta‐analysis ,Glycated hemoglobin ,business - Abstract
Aims/Introduction This systematic review and meta‐analysis aimed to investigate the efficacy and safety of acceptance and commitment therapy (ACT) for people with type 2 diabetes mellitus. Materials and Methods Several electronic databases were examined on 16 January 2021, including PubMed, CENTRAL, PsycINFO, International Clinical Trials Registry Platform and ClinicalTrials.gov. Randomized controlled trials were included to compare ACT with usual treatment for people with type 2 diabetes reported in any language. Primary outcome measures were glycated hemoglobin, self‐care ability assessed by the summary of diabetes self‐care activities and all adverse events. The secondary outcome measure was acceptance assessed by the acceptance and action diabetes questionnaire. Results Of 678 publications initially identified, three trials were included in the meta‐analysis. ACT resulted in a reduction in glycated hemoglobin (mean difference −0.62 points lower in the intervention group; 95% confidence interval −1.07 to −0.16; I2 = 0%; low‐quality evidence). In addition, ACT increased the score of the summary of diabetes self‐care activities (mean difference 8.48 points higher in the intervention group; 95% confidence interval 2.16–14.80; high‐quality evidence). Adverse events were not measured in all trials. ACT increased scores of the acceptance and action diabetes questionnaire (mean difference 5.98 points higher in the intervention group; 95% confidence interval, 1.42–10.54; I2 = 43%; low‐quality evidence). Conclusions ACT might reduce glycated hemoglobin, and increase self‐care ability and acceptance among people with type 2 diabetes.
- Published
- 2022
4. A digest of the Evidence-Based Clinical Practice Guideline for Nephrotic Syndrome 2020
- Author
-
Rei Miyata, Yoshitaka Miyaoka, Tomo Suzuki, Ichiei Narita, Izaya Nakaya, Yoshihiro Yamamoto, Takuji Ishimoto, Yuya Itano, Sayaka Shimizu, Daisuke Ichikawa, Kazuhiro Sugiyama, Yuji Oe, Kengo Furuichi, Tomomi Tanaka, Hideaki Shima, Hirokazu Okada, Midori Hasegawa, Hideyo Oguchi, Hiroki Nishiwaki, Masahiro Koizumi, Shiho Kosaka, Kandai Nozu, Takehiko Wada, Tadashi Sofue, Sho Sasaki, Yugo Shibagaki, Kakuya Niihata, Mai Yoshida, Sayuri Shirai, Daisuke Son, Shoji Saito, Yoko Nishijima, Shinichi Akiyama, Satoshi Kohsaka, Takehiko Kawaguchi, Masahiko Yazawa, Nobuhiro Nishibori, Yuki Kataoka, Takaya Ozeki, Eishu Nango, Masaki Okazaki, Ryohei Yamamoto, and Noriaki Kurita
- Subjects
Nephrology ,medicine.medical_specialty ,Nephrotic Syndrome ,Evidence-based practice ,Physiology ,business.industry ,MEDLINE ,Guideline ,medicine.disease ,Clinical Practice ,Evidence-Based Practice ,Physiology (medical) ,Internal medicine ,medicine ,Humans ,business ,Intensive care medicine ,Nephrotic syndrome ,Immunosuppressive Agents - Published
- 2021
5. Association of low birthweight and premature birth with hypertensive disorders in pregnancy: a systematic review and meta-analysis
- Author
-
Yoshiko Yamamoto, Shunsuke Taito, Yasushi Tsujimoto, Yuko Masuzawa, Masayo Kokubo, Masahiro Banno, and Yuki Kataoka
- Subjects
medicine.medical_specialty ,Pregnancy ,Physiology ,business.industry ,Obstetrics ,Infant, Newborn ,Pregnancy Outcome ,Hypertension, Pregnancy-Induced ,Infant, Low Birth Weight ,medicine.disease ,Pregnancy Complications ,Premature birth ,Meta-analysis ,Internal Medicine ,medicine ,Birth Weight ,Humans ,Premature Birth ,Female ,Cardiology and Cardiovascular Medicine ,Association (psychology) ,business - Abstract
Growing evidence suggests that women born preterm or small have an increased risk of experiencing hypertensive disorders during pregnancy; however, a quantitative summary of the evidence on this issue is unavailable.We aimed to systematically review the literature to describe the association between being born preterm, low birthweight (LBW), or small for gestational age (SGA), and future gestational hypertension, preeclampsia, or eclampsia.We searched the MEDLINE, Embase, CINAHL, ClinicalTrials.gov, and ICTRP databases. We included all cohort and case-control studies examining the association between LBW, preterm birth, or SGA and hypertensive disorders in pregnancy. We pooled the odds ratios and 95% confidence intervals using the DerSimonian and Laird random-effects model. We assessed the certainty of evidence for each outcome using the Grading of Recommendations, Assessment, Development, and Evaluation criteria.Eleven studies were identified, totalling 752 316 participants. Being born preterm, LBW, or SGA was associated with gestational hypertension [pooled odds ratio (OR), 1.31; 95% confidence interval (CI) 1.15-1.50; moderate certainty of evidence] and preeclampsia (pooled OR, 1.35; 95% CI 1.23-1.48; moderate certainty of evidence). No study measured eclampsia as an outcome.Women born preterm, LBW, or SGA have an increased risk of gestational hypertension and preeclampsia. The course of the mother's own birth might be used to identify women at risk of gestational hypertension and preeclampsia.
- Published
- 2021
6. Optimization of prediction methods for risk assessment of pathogenic germline variants in the Japanese population
- Author
-
Kaori Togashi, Akira Yamauchi, Hironori Kato, Nobuhiko Shinkura, Kenichi Yoshida, Kosuke Kawaguchi, Takahiro Yamada, Ryuji Okamura, Masahiro Sugimoto, Eiji Suzuki, Hironori Haga, Masae Torii, Hirofumi Suwa, Norimichi Kan, Sachiko Takahara, Yoshiaki Matsumoto, Masahiro Kawashima, Tsuyoshi Tachibana, Masakazu Toi, Yukiko Inagaki-Kawata, Hiroshi Yoshibayashi, Takashi Inamoto, Masako Kataoka, Shingo Sakata, Nobuko Kawaguchi-Sakita, Fumiaki Yotsumoto, Kazuhiko Yamagami, Yuki Kataoka, Mitsuru Tanaka, Shinji Kosugi, Masahiro Takada, Seishi Ogawa, Shigeru Tsuyuki, Tomomi Nishimura, Susumu Mashima, Noriko Senda, and Yoshio Moriguchi
- Subjects
0301 basic medicine ,Oncology ,Genetics, Genomics and Proteomics ,Cancer Research ,BRCA ,0302 clinical medicine ,Japan ,Mutation Rate ,Age of Onset ,Aged, 80 and over ,Ovarian Neoplasms ,BRCA1 Protein ,Genetic Carrier Screening ,pathogenic germline variant ,General Medicine ,Middle Aged ,Pedigree ,risk factor ,030220 oncology & carcinogenesis ,Population Surveillance ,Original Article ,Female ,Risk assessment ,Fanconi Anemia Complementation Group N Protein ,Adult ,medicine.medical_specialty ,PALB2 ,Breast Neoplasms ,Risk Assessment ,03 medical and health sciences ,Tyrer‐Cuzick model ,Breast cancer ,breast cancer ,Internal medicine ,medicine ,Humans ,Genetic Predisposition to Disease ,Risk factor ,Tyrer-Cuzick Model ,Germ-Line Mutation ,Aged ,BRCA2 Protein ,business.industry ,Tyrer-Cuzick model ,Cancer ,Original Articles ,medicine.disease ,Confidence interval ,030104 developmental biology ,business ,Ovarian cancer - Abstract
Predicting pathogenic germline variants (PGVs) in breast cancer patients is important for selecting optimal therapeutics and implementing risk reduction strategies. However, PGV risk factors and the performance of prediction methods in the Japanese population remain unclear. We investigated clinicopathological risk factors using the Tyrer‐Cuzick (TC) breast cancer risk evaluation tool to predict BRCA PGVs in unselected Japanese breast cancer patients (n = 1,995). Eleven breast cancer susceptibility genes were analyzed using target‐capture sequencing in a previous study; the PGV prevalence in BRCA1, BRCA2, and PALB2 was 0.75%, 3.1%, and 0.45%, respectively. Significant associations were found between the presence of BRCA PGVs and early disease onset, number of familial cancer cases (up to third‐degree relatives), triple‐negative breast cancer patients under the age of 60, and ovarian cancer history (all P, Combination of major clinicopathological risk factors and predictive scores could help identify and characterize high‐risk population carrying BRCA1/2 PGVs among Japanese breast cancer patients. Significant associations were found between the presence of PGVs and early disease onset, number of familial cancer cases within third‐degree relatives, triple‐negative breast cancer patients under the age of 60, and ovarian cancer history (all P
- Published
- 2021
7. Efficacy of Metformin in Patients With Breast Cancer Receiving Chemotherapy or Endocrine Therapy: Systematic Review and Meta-analysis
- Author
-
Yuki Kataoka, Nobuko Kawaguchi-Sakita, Akihiro Shiroshita, Yasuko Kurata, and Kayoko Morio
- Subjects
Oncology ,medicine.medical_specialty ,medicine.medical_treatment ,Breast Neoplasms ,03 medical and health sciences ,0302 clinical medicine ,Breast cancer ,Internal medicine ,medicine ,Humans ,Pharmacology (medical) ,In patient ,030212 general & internal medicine ,Chemotherapy ,business.industry ,Endocrine therapy ,medicine.disease ,Metformin ,Neoadjuvant Therapy ,Chemotherapy, Adjuvant ,030220 oncology & carcinogenesis ,Meta-analysis ,Female ,Neoplasm Recurrence, Local ,business ,medicine.drug - Abstract
Background Previous studies have suggested that metformin might improve survival outcomes in patients with breast cancer. However, findings on the efficacy of metformin with chemotherapy or endocrine therapy are inconsistent. Objective To clarify the efficacy of metformin with chemotherapy or endocrine therapy in breast cancer patients according to the treatment setting, including neoadjuvant, adjuvant, and metastasis/recurrence. Methods We systematically searched for randomized controlled trials (RCTs) in MEDLINE, CENTRAL, and EMBASE from inception through July 2020. Overall survival (OS), progression-free survival (PFS), and hypoglycemia rate were the primary outcomes. Secondary outcomes included severe adverse events (SAEs) and relapse-free survival. We used the Grading of Recommendations Assessment, Development, and Evaluation approach and performed a meta-analysis to evaluate the efficacy and safety of metformin with chemotherapy and endocrine therapy in patients with breast cancer. Results Our systematic review included 412 participants from 5 trials. Metformin showed little to no difference in OS (hazard ratio [HR] = 1.13; 95% CI = 0.71-1.81; certainty of evidence [COE], moderate) and PFS (HR = 1.14; 95% CI = 0.86-1.50; COE, moderate) in patients with metastasis/recurrence. The evidence was very uncertain about the effect of metformin on survival outcomes in patients who received metformin with neoadjuvant or adjuvant treatment. Metformin showed little to no difference in hypoglycemia and SAEs. Conclusion and Relevance Metformin should be discouraged routinely in nondiabetic patients with metastatic/recurrent breast cancer. Further RCTs are needed to verify whether metformin with chemotherapy or endocrine therapy results in significant clinical benefits in the neoadjuvant or adjuvant setting.
- Published
- 2021
8. International consensus on severe lung cancer—the first edition
- Author
-
Yi Hu, Mengzhao Wang, Xinlin Mu, Liyun Miao, Zhengfei Zhu, Lin Wu, Chengping Hu, Dongsheng Yue, Zongyang Yu, Xiuyu Cai, Yihong Shen, Weifeng Li, Huijuan Wang, Kai Wang, Shiyue Li, Jian Zhang, Alfonso Fiorelli, Min Li, Chunxia Su, Gengyun Sun, Liangan Chen, Caicun Zhou, Ming Liu, Wen Dong, Wei Zhang, Hitoshi Igai, Linbo Cai, Meng Yang, Nanshan Zhong, Yong He, Qian Chu, Qi Wang, Yoshinobu Ichiki, Jun Liu, Kejing Tang, Yang Jin, Shengxiang Ren, Taichiro Goto, Ziming Li, Yong Song, Feng Ye, Piergiorgio Solli, Yuehong Wang, Yuichi Saito, Wenfeng Fang, Xinqing Lin, Xiangjun Yi, Fei Xu, Wenhua Liang, Bo Zhu, Yuchao Dong, Gen Lin, Jianying Zhou, Wei Zhao, Ping Wang, Hongbing Liu, Chengzhi Zhou, Jie Hu, Chunxue Bai, Xiaoju Zhang, Nikolaos Tsoukalas, Yu Chen, Jianxing He, Yanbin Zhou, Jie Lin, Sara Bravaccini, Jianqing Zhang, Wen-Zhao Zhong, Xiaohong Xie, Baohui Han, Xin Xu, Boyan Yang, Bicheng Zhang, Hongmei Wang, Jie Wang, Zhanhong Xie, Zhijie Wang, Satoshi Watanabe, Weimin Li, Yuki Kataoka, Takeo Nakada, Shun Lu, Yinyin Qin, Fei Cui, Francesco Petrella, Xiaoqun Ye, and Rossana Berardi
- Subjects
COPD ,medicine.medical_specialty ,Consensus ,Performance status ,business.industry ,medicine.medical_treatment ,Disease ,medicine.disease ,Targeted therapy ,Radiation therapy ,Oncology ,Internal medicine ,medicine ,Extracorporeal membrane oxygenation ,Adenocarcinoma ,Lung cancer ,business - Abstract
Lung cancer is one of the most prevalent and lethal cancers worldwide (1). The traditional treatments include surgery, chemotherapy, radiotherapy and interventional therapy. The survival of lung cancer patients has dramatically been prolonged in recent years with the availability of targeted therapies, antiangiogenic agents and immune checkpoint inhibitors (ICIs). Meanwhile, technologies for the molecular detection of lung cancer have also advanced rapidly: the detection of single driver genes has evolved to cover combined multi-gene analysis, and whole exome sequencing (WES) has increasingly been applied in the clinical setting. In addition, life support technologies, including ventilators, artificial liver, and artificial kidney as well as extracorporeal membrane oxygenation (ECMO), have further matured, providing powerful forms of life support for patients with various acute and critical diseases. However, most clinical studies have only enrolled patients with Eastern Cooperative Oncology Group (ECOG) performance status (PS) scores from 0 to 1, with few patients having PS scores of 2; patients with a PS score of 3 or 4 have been typically excluded. Therefore, due to the lack of high-quality evidence, supportive care is recommended for patients with a PS score of 3 to 4 in the current guidelines. In the real-world, however, approximately 25% of lung cancer patients present with PS score of 3 or 4 (2) or attain scores between 3 and 4 during the course of treatment. Certain patients with high PS scores can benefit from individualized anti-tumor treatment plus appropriate life-support techniques. In 2017, the Lung Cancer Research Team at the First Affiliated Hospital of Guangzhou Medical College & Institute of Respiratory Diseases for the first time pioneered the concept of “advanced severe lung cancer” (3) and argued that standardized therapy for chronic obstructive pulmonary disease (COPD) plus anti-tumor therapy can improve both quality of life and prognosis in patients with lung cancer combined with COPD. The authors also found that the early detection of lung cancer driver genes and timely targeted therapy can be successful in treating patients with advanced severe lung adenocarcinoma with a PS score of 4 (4). In 2019, the concept of advanced severe lung cancer was further developed in a featured article (5) that indicated “Advanced severe lung cancer: does not refer to end-stage lung cancer but rather to stage IIIB, IIIC and IV lung cancers with a PS score of 2–4, which can result from a variety of factors related to the disease itself or anti-tumor drugs and which are highly likely to benefit from the currently available systemic anti-tumor therapies”. In recent years, with the advances in lung cancer diagnosis and treatment techniques and life support technologies, more clinical studies have enrolled patients with a PS score of 2, and some real-world studies have enrolled patients with PS scores of 3–4. Even for patients with early-stage lung cancer, studies have shown that patients with poor PS scores and co-morbidities have a reduced chance of undergoing surgery and an increased mortality rate (6); nevertheless, survival benefit may still be obtained through surgical modifications combined with individualized and multidisciplinary treatment (7). Therefore, the concept of severe lung cancer should not be limited to advanced lung cancer, but applied to all lung cancer patients. In particular, due to the increase in treatment options as well as substantially prolonged survival, the majority of patients may have a PS score between 2 and 4 for a certain period of time due to a variety of reasons. How to provide timely and reasonable treatment for these lung cancer patients has become a critically important real-world research topic. Therefore, we invited lung cancer experts at home and abroad to consider this issue, and this group has reached the following consensus.
- Published
- 2021
9. Influence of loneliness and social isolation on the diagnosis and treatment of Japanese patients with advanced lung cancer: a prospective cohort study
- Author
-
Yuki Kataoka, Azusa Sakurai, Shunkichi Ikegaki, Emiko Saito, Nobuko Wada, Masatoshi Shimada, Reika Iki, Takehiro Otoshi, Sawako Kaku, Takuma Imakita, Mariko Shinomiya, Koya Okazaki, Hirohito Takata, Katsuya Hirano, Hirotaka Matsumoto, Toru Naganuma, Tomoyasu Takemura, Masataka Hirabayashi, Kazuo Endo, Junichi Nikaido, Chigusa Shirakawa, and Tomoyuki Hirai
- Subjects
medicine.medical_specialty ,Lung Neoplasms ,Gene mutation ,Tertiary referral hospital ,03 medical and health sciences ,0302 clinical medicine ,Japan ,Internal medicine ,medicine ,Humans ,Prospective Studies ,030212 general & internal medicine ,Social determinants of health ,Social isolation ,Lung cancer ,Prospective cohort study ,Advanced and Specialized Nursing ,Performance status ,business.industry ,Loneliness ,medicine.disease ,Anesthesiology and Pain Medicine ,Social Isolation ,030220 oncology & carcinogenesis ,medicine.symptom ,business - Abstract
Background Social determinants of health (SDHs) are social factors that affect human health; loneliness and social isolation are core SDH factors. There is a possibility that SDHs are related to passive decisionmaking. However, few studies have evaluated SDHs, especially social isolation and loneliness, among lung cancer patients. This study aims to investigate the effects of social isolation and loneliness on the diagnosis and treatment of Japanese lung cancer patients. Methods This is a prospective cohort study that was conducted in a tertiary referral hospital in Japan (University Hospital Medical Information Network registration: UMIN000031810). The enrollment period was between April 2018 and March 2020. Patients with clinical and/or pathological diagnosis of lung cancer were enrolled in this study. Exposures were social isolation and loneliness, and main outcomes were diagnosis methods and whether the initial treatment involved active therapy or best supportive care (BSC). The confounding factors were defined as sex, age, smoking status, respiratory symptoms, weight loss, presentation with any symptoms, Eastern Cooperative Oncology Group (ECOG) performance status, tumor nodes metastasis (TNM) classification, driver gene mutations [i.e., epidermal growth factor receptor (EGFR), anaplastic lymphoma kinase (ALK)], and programmed death-ligand 1 (PD-L1) tumor proportion score. Results The study enrolled 264 patients who were divided into quartiles according to their loneliness scores and into two groups according to the social isolation level. Univariate analysis, complete case analysis, and multivariate analysis with multiple imputation failed to detect significant differences in diagnostic method or initial treatment strategy according to loneliness or social isolation level. Conclusions Physicians may not need to consider a patient's loneliness and/or social isolation when diagnosing lung cancer and selecting treatment under universal health insurance coverage. Further studies are needed to understand the influences of loneliness and social isolation on the prognosis of lung cancer patients.
- Published
- 2021
10. Effectiveness of Steroid Therapy on Pneumonic Chronic Obstructive Pulmonary Disease Exacerbation: A Multicenter, Retrospective Cohort Study
- Author
-
Akihiro Nishi, Chigusa Shirakawa, Yu Tanaka, Kenya Sato, Hiroshi Shiba, Yuki Kataoka, and Akihiro Shiroshita
- Subjects
COPD ,medicine.medical_specialty ,Exacerbation ,business.industry ,Confounding ,Retrospective cohort study ,General Medicine ,medicine.disease ,law.invention ,03 medical and health sciences ,0302 clinical medicine ,030228 respiratory system ,Randomized controlled trial ,law ,Heart failure ,Internal medicine ,Propensity score matching ,medicine ,Observational study ,030212 general & internal medicine ,business - Abstract
Purpose To date, no consensus exists on the effects of systemic steroid use on pneumonic chronic obstructive pulmonary disease (COPD) exacerbation owing to trial design issues in previous trials involving these conditions. This multicenter study aimed to evaluate more precisely the effectiveness of the use of systemic steroids in treating pneumonic COPD exacerbation in a larger sample by adjusting for confounding factors. Patients and methods This multicenter, retrospective, observational study was conducted across five acute general hospitals in Japan. We analyzed the association between parenteral/oral steroid therapy and time to clinical stability in pneumonic COPD exacerbation. We used a validated algorithm derived from the 10th revision of the International Classification of Diseases and Related Health Problems (ICD-10) to include patients with pneumonic COPD exacerbation. We excluded patients with other hypoxia causes (asthma exacerbation, pneumothorax, heart failure) and complicated pneumonia (obstructive pneumonia, empyema), those who required tracheal intubation/vasopressors, and those who were clinically stable on day of admission. The primary outcome was the time to clinical stability. Multiple imputation was used for missing data. Propensity scores within each imputed dataset were calculated using potential confounding factors. The Fine and Gray model was used within each dataset to account for the competing risk of death and hospital discharge without clinical stability, and we combined the results. Results Altogether, 1237 patients were included. Systemic steroid therapy was administered to 658 patients (53%). The pooled estimated subdistribution hazard ratio of time to clinical stability in steroid vs non-steroid users was 0.89 (95% confidence interval, 0.78 to 1.0). Conclusion This study revealed that systemic steroid therapy may not improve the time to clinical stability in patients with pneumonic COPD exacerbation of mild to moderate severity. Further randomized controlled trials including more severe patients will be needed to evaluate the effectiveness of systemic steroid therapy accurately.
- Published
- 2020
11. Abstract P2-10-12: Relationship between predicted risks of carrying breast cancer susceptibility genes and the presence of germline variants in Japanese patients with primary breast cancer
- Author
-
Takashi Inamoto, Fumiaki Yotsumoto, Masahiro Kawashima, Masae Torii, Hiroshi Yoshibayashi, Masakazu Toi, Akira Yamauchi, Kenichi Yoshida, Nobuko Kawaguchi-Sakita, Mitsuru Tanaka, Shingo Sakata, Masahiro Sugimoto, Hirofumi Suwa, Nobuhiko Shinkura, Shigeru Tsuyuki, Yukiko Inagaki-Kawata, Yuki Kataoka, Yoshiaki Matsumoto, Tomomi Nishimura, Norimichi Kan, K Yamagami, Ryuji Okamura, Susumu Mashima, Fumiaki Sato, Hironori Kato, Yoshio Moriguchi, Noriko Senda, Tsuyoshi Tachibana, Masahiro Takada, Seishi Ogawa, and Eiji Suzuki
- Subjects
Oncology ,Cancer Research ,medicine.medical_specialty ,medicine.diagnostic_test ,business.industry ,PALB2 ,Cancer ,Retrospective cohort study ,medicine.disease ,Breast cancer ,Internal medicine ,medicine ,Mammography ,skin and connective tissue diseases ,Ovarian cancer ,business ,CHEK2 ,Genetic testing - Abstract
Background: Breast cancer risk models are used to predict the risk of carrying a variant, for one of the most common breast cancer susceptibility genes such as BRCA1 and BRCA2, and the lifetime risk of developing breast cancer. The prediction of harboring a germline variant of the BRCA gene and the development of breast or ovarian cancer over time affects the decision-making for undergoing genetic testing and screening using imaging techniques as the common practice. For instance, the American Cancer Society and the National Comprehensive Cancer Network (NCCN) recommends screening using MRI in women with 20% or greater lifetime risk of having breast cancer. We aimed to investigate the prediction of these risks in Japanese women, particularly on the relationship between the presence of pathogenic germline variants and breast cancer susceptibility genes, using a cohort of 1016 primary breast cancer patients. Patients and Methods: We analyzed a cohort of Japanese patients with primary breast cancer who were treated at the Kyoto University Hospital and the related institutions or hospitals from the period of 2011 to 2016. The germline variants were examined for a set of 13 breast cancer susceptibility genes, using targeted-capture sequencing of pooled DNA, and it was found that 66 out of 1016 patients had pathogenic variants. These included 11 functionally well-established genes (BRCA1, BRCA2, TP53, PTEN, CDH1, STK11, NF1, PALB2, ATM, CHEK2, and NBN) and two additional genes (BARD1 and BRIP1), which are recommended for the screening of high-risk patients with hereditary breast cancer in the NCCN guidelines. Using this cohort, we studied the association of the calculated risk of carrying a germline variant of BRCA1/ BRCA2, using the Tyrer-Cuzick model Breast Cancer Risk Evaluation Tool, within the laboratory germline test results. Results: Pathogenic germline variants of BRCA1/ BRCA2 were carried by 54 (5.3%) out of the 1016 patients (12 cases of BRCA1 and 42 cases of BRCA2). According to the NCCN guidelines, which focus on Genetic/ Familial High-Risk Assessment: Breast and Ovarian, it was found that 500 out of 1016 (49.2%)patients were categorized for considering germline testing. In fact, 38 (7.6%) of the 500 patients, harbored a pathogenic germline variant of BRCA1/ BRCA2. In the remaining 516 patients, 16 (3.1%) harbored the pathogenic germline variant of BRCA1/ BRCA2. The predictive risks of the Tyrer-Cuzick model Breast Cancer Risk Evaluation Tool were recorded as follows: Area under the ROC curve, BRCA1 (area 0.750, 95% CI- 0.581-0.919), BRCA2 (area 0.741, 95% CI- 0.661-0.820), BRCA1 or BRCA2 (Area 0.749, 95% CI: 0.675-0.822), suggesting that the Tyrer-Cuzick model may be useful for the Japanese population. In the mammography breast density analysis, 484 patients showed almost entirely fat or scattered fibroglandular breast tissue, and 362 cases had heterogeneous or extreme fibroglandular breast tissue. In this study, the correlations of breast tissue density with age and breast or ovarian cancer familial history have been reported in greater detail. Discussion and Conclusions: In a retrospective cohort of 1016 Japanese patients with primary breast cancer, 5.3% had pathogenic germline variants of BRCA1/ BRCA2. In a group recommended by NCCN guidelines for considering genetic testing, the BRCA1/ BRCA2 variant rate was 7.6%. Predictive risks calculated by the Tyrer-Cuzick model similar with the known data. Further data are reported. Citation Format: Noriko Senda, Nobuko Kawaguchi-Sakita, Masahiro Kawashima, Yukiko Inagaki-Kawata, Kenichi Yoshida, Tomomi Nishimura, Masahiro Takada, Eiji Suzuki, Yuki Kataoka, Fumiaki Sato, Yoshiaki Matsumoto, Masae Torii, Hiroshi Yoshibayashi, Kazuhiro Yamagami, Shigeru Tsuyuki, Akira Yamauchi, Nobuhiko Shinkura, Hironori Kato, Yoshio Moriguchi, Ryuji Okamura, Norimichi Kan, Hirofumi Suwa, Shingo Sakata, Susumu Mashima, Fumiaki Yotsumoto, Tsuyoshi Tachibana, Mitsuru Tanaka, Takashi Inamoto, Masahiro Sugimoto, Seishi Ogawa, Masakazu Toi. Relationship between predicted risks of carrying breast cancer susceptibility genes and the presence of germline variants in Japanese patients with primary breast cancer [abstract]. In: Proceedings of the 2019 San Antonio Breast Cancer Symposium; 2019 Dec 10-14; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2020;80(4 Suppl):Abstract nr P2-10-12.
- Published
- 2020
12. Predictors of duloxetine response in patients with neuropathic cancer pain: a secondary analysis of a randomized controlled trial—JORTC-PAL08 (DIRECT) study
- Author
-
Yoshinobu Matsuda, Tatsuya Morita, K. Sakai, Yuki Kataoka, Satoru Iwase, Akihiro Tokoro, Keisuke Ariyoshi, Tempei Miyaji, Hideaki Hasuo, Yoichi Ohtake, Shunsuke Oyamada, Hiromichi Matsuoka, Atsuko Koyama, Hiroto Ishiki, Hiroaki Tsukuura, Kazuki Tahara, Yoshihisa Matsumoto, Miki Nakura, Takuhiro Yamaguchi, Yoshikazu Hasegawa, Hiroyuki Otani, Masatomo Otsuka, Hiroko Sakuma, Takashi Kawaguchi, and Eriko Satomi
- Subjects
medicine.medical_specialty ,business.industry ,Pregabalin ,Hospital Anxiety and Depression Scale ,law.invention ,03 medical and health sciences ,chemistry.chemical_compound ,0302 clinical medicine ,Oncology ,Opioid ,Randomized controlled trial ,chemistry ,law ,McGill Pain Questionnaire ,030220 oncology & carcinogenesis ,Internal medicine ,Neuropathic pain ,medicine ,Duloxetine ,030212 general & internal medicine ,business ,Cancer pain ,medicine.drug - Abstract
Duloxetine has some effect against cancer neuropathic pain (CNP); however, predictors of duloxetine response are unclear. This study sought to identify predictors of duloxetine response in patients with CNP. Patients (N = 70) with CNP unresponsive to or intolerant of opioid–pregabalin combination therapy, with a brief pain inventory-short form (BPI-SF) Item 5 score (average pain) ≥ 4, and with a total hospital anxiety and depression scale score < 20, were randomized to a duloxetine or a placebo group. Multiple linear regression analysis was conducted to identify predictors of duloxetine response as a secondary analysis with the change in the average pain score on day 10 from day 0 as the dependent variable, and the following five covariates; baseline (day 0) average pain score, baseline opioid dose, continuation/discontinuation of pregabalin, and items 20 and 21 score of the short-form McGill pain questionnaire 2 (SF-MPQ-2) as independent variables. Of the four domains (continuous pain, intermittent pain, neuropathic pain, and affective descriptors) score of SF-MPQ-2 on day 0, significant differences were observed in the neuropathic pain domain (p = 0.040) in change on the average pain between day 10 and day 0 in the duloxetine group. Multiple linear regression analysis revealed that patients with a high score for SF-MPQ-2 Item 21 (tingling pain) on day 0 had a significantly greater change in average pain between day 10 and day 0 (p = 0.046). Patients with a high score for SF-MPQ-2 Item 21 might benefit more from duloxetine.
- Published
- 2019
13. Effectiveness of angiotensin converting enzyme inhibitors in preventing pneumonia: A systematic review and meta-analysis
- Author
-
Hideki Tsunoda, Yukiko Okami, Yuki Honda, Akihiro Shiroshita, Yuki Kataoka, Yasushi Tsujimoto, and Kazuhiro Matsumura
- Subjects
angiotensin-converting enzyme inhibitors ,Internal Medicine ,pneumonia ,Geriatrics and Gerontology ,Family Practice ,mortality ,risk - Abstract
We performed a systematic review and meta-analysis to re-evaluate the effectiveness of angiotensin-converting enzyme inhibitors (ACE-I) in the reduction of pneumonia risk. We searched relevant publications in five databases. All studies included patients older than 18 years, who had used ACE-I as an intervention, and had assessed pneumonia. Seven RCTs (n = 8704) and 38 observational studies (n = 1,705,030) were included. The overall risk of bias was high. ACE-I-treated patients were associated with a slightly lower risk of pneumonia, both from pooled estimates of RCTs [pooled odds ratio (OR), 0.75; 95% confidence interval (CI), 0.62–0.90; low certainty of evidence] and observational studies (pooled OR, 0.85; 95% CI, 0.78–0.92; very low certainty of evidence). Considering the small effect size of ACE-I in preventing pneumonia and the low quality of the evidence, routine use of ACE-I for pneumonia prevention is not recommended.
- Published
- 2021
14. Effectiveness of empirical anti-pseudomonal antibiotics for recurrent COPD exacerbation: a multicenter retrospective cohort study
- Author
-
Keisuke Tomii, Chisato Miyakoshi, Yuki Kataoka, Kenya Sato, Hiroshi Shiba, Akihiro Shiroshita, Masahiro Ohgiya, Shinya Matsushita, Chigusa Shirakawa, Yuya Kimura, and Shunta Tsutsumi
- Subjects
Adult ,Male ,medicine.medical_specialty ,Exacerbation ,medicine.drug_class ,Science ,Antibiotics ,Article ,Pulmonary Disease, Chronic Obstructive ,Medical research ,Recurrence ,Internal medicine ,Humans ,Medicine ,Pseudomonas Infections ,Generalized estimating equation ,Retrospective Studies ,COPD ,Multidisciplinary ,business.industry ,Health care ,Retrospective cohort study ,Prognosis ,medicine.disease ,Confidence interval ,Anti-Bacterial Agents ,Pseudomonas aeruginosa ,Disease Progression ,Sputum ,Female ,medicine.symptom ,business ,Body mass index - Abstract
Although frequent chronic obstructive pulmonary disease (COPD) exacerbation has been associated with the isolation of Pseudomonas aeruginosa (PA) in sputum cultures, it remains unknown whether the empirical use of anti-pseudomonal antibiotics can improve outcomes in patients with frequent COPD exacerbations. This multicenter retrospective cohort study evaluated whether the empirical use of anti-pseudomonal antibiotics improves the length of the hospital stay in patients with recurrent COPD exacerbation (≥ 2 admissions from April 1, 2008 to July 31, 2020). For statistical analysis, a log-linked Gamma model was used. Parameters were estimated using a generalized estimating equation model with an exchangeable correlation structure accounting for repeated observations from a single patient. Covariates included age, body mass index, home oxygen therapy use, respiratory rate, heart rate, oxygen use on admission, mental status, systemic steroid use, activities of daily living, and the number of recurrences. Hospital-specific effects were specified as fixed effects. In total, 344 patients and 965 observations of recurrent COPD exacerbations were selected. Anti-pseudomonal antibiotics were used in 173 patients (18%). The estimated change in the length of the hospital stay between anti-pseudomonal and non-anti-pseudomonal antibiotics groups was 0.039 days [95% confidence interval; − 0.083, 0.162]. Anti-pseudomonal antibiotics could not shorten the length of the hospital stay.
- Published
- 2021
15. The prognostic factors of in-hospital death among patients with pneumonic COPD acute exacerbation
- Author
-
Yuki Kataoka, Kenya Sato, Akihiro Shiroshita, Keisuke Tomii, Chigusa Shirakawa, Shinya Matsushita, and Hiroshi Shiba
- Subjects
In hospital death ,Pulmonary and Respiratory Medicine ,medicine.medical_specialty ,COPD ,Exacerbation ,business.industry ,medicine.disease ,Prognosis ,Hospitalization ,Pulmonary Disease, Chronic Obstructive ,Risk Factors ,Internal medicine ,medicine ,Disease Progression ,Humans ,Hospital Mortality ,business ,Lung ,Retrospective Studies - Abstract
Purpose: Pneumonic acute exacerbation of chronic obstructive pulmonary disease (COPD-AE) is associated with worse outcomes compared with non-pneumonic COPD-AE. Currently, only one study has been evaluated the prognostic factors of pneumonic COPD-AE; the study is limited by sample size, and ignoring heterogeneity of the treatment strategy. Thus, we aimed to include more patients and explore the more focused prognostic factors of patients with pneumonic COPD-AE who were treated with systemic steroids. Patients and methods: This multicentered retrospective cohort study was conducted across five acute hospitals in Japan. Hospitalized patients ≥ 40 years of age with pneumonic COPD-AE who were administered systemic corticosteroids during hospitalization were included. Patients with other causes of respiratory failure (heart failure, pneumothorax, asthma exacerbation, and obstructive pneumonia), daily systemic steroids users, and patients who were not treated with systemic steroids were excluded. The following potential prognostic factors were selected in advance based on the existing clinical prediction models: age (> 70 years), eosinophilic count ( ≥ 0.05 × 109 /L), blood urea nitrogen (> 7 mmol/L), respiratory rate (≥ 30/min), diastolic blood pressure (≤ 60 mmHg), and altered mental status. Multivariate logistic regression was conducted to determine whether the potential prognostic factors were associated with in-hospital death.Results: After excluding 897 patients based on the exclusion criteria, 669 patients with pneumonic COPD-AE who were administered systemic corticosteroids were included. The in-hospital mortality rate was 5.1 %; the median age was 78.0; 15 patients were intubated; and the median length of hospital was 12 days. Altered mental status was associated with mortality (odds ratio, 4.47; 95% confidence intervals, 2.00 to 10.00]) and a high eosinophil count was associated with a lower risk of mortality (odds ratio, 0.19; 95% confidence intervals: 0.06 to 0.56).Conclusion: Altered mental status may be the prognostic factor of in-hospital death among patients with pneumonic COPD-AE who are receive systemic corticosteroids. Moreover, high eosinophilia may be a prognostic factor for lower in-hospital mortality in hospital among these patients.
- Published
- 2021
16. Monitoring of gastric residual volume during enteral nutrition
- Author
-
Natsuki Kondo, Sadaharu Asami, Hideto Yasuda, Takayuki Abe, Hiraku Tsujimoto, Yasushi Tsujimoto, Yuki Kataoka, and Ryohei Yamamoto
- Subjects
Medicine General & Introductory Medical Sciences ,medicine.medical_specialty ,business.industry ,Mortality rate ,Incidence (epidemiology) ,education ,Stomach ,Length of Stay ,Aspiration pneumonia ,medicine.disease ,Confidence interval ,law.invention ,Residual Volume ,Intensive Care Units ,Regimen ,Enteral Nutrition ,Randomized controlled trial ,law ,Internal medicine ,Relative risk ,Intensive care ,Humans ,Medicine ,Pharmacology (medical) ,business - Abstract
Background The main goal of enteral nutrition (EN) is to manage malnutrition in order to improve clinical outcomes. However, EN may increase the risks of vomiting or aspiration pneumonia during gastrointestinal dysfunction. Consequently, monitoring of gastric residual volume (GRV), that is, to measure GRV periodically and modulate the speed of enteral feeding according to GRV, has been recommended as a management goal in many intensive care units. Yet, there is a lack of robust evidence that GRV monitoring reduces the level of complications during EN. The best protocol of GRV monitoring is currently unknown, and thus the precise efficacy and safety profiles of GRV monitoring remain to be ascertained. Objectives To investigate the efficacy and safety of GRV monitoring during EN. Search methods We searched electronic databases including CENTRAL, MEDLINE, Embase, and CINAHL for relevant studies on 3 May 2021. We also checked reference lists of included studies for additional information and contacted experts in the field. Selection criteria We included randomized controlled trials (RCTs), randomized cross-over trials, and cluster-RCTs investigating the effects of GRV monitoring during EN. We imposed no restrictions on the language of publication. Data collection and analysis Two review authors independently screened the search results for eligible studies and extracted trial-level information from each included study, including methodology and design, characteristics of study participants, interventions, and outcome measures. We assessed risk of bias for each study using Cochrane's risk of bias tool. We followed guidance from the GRADE framework to assess the overall certainty of evidence across outcomes. We used a random-effects analytical model to perform quantitative synthesis of the evidence. We calculated risk ratios (RRs) with 95% confidence intervals (CIs) for dichotomous and mean difference (MD) with 95% CIs for continuous outcomes. Main results We included eight studies involving 1585 participants. All studies were RCTs conducted in ICU settings. Two studies (417 participants) compared less-frequent (less than eight hours) monitoring of GRV against a regimen of more-frequent (eight hours or greater) monitoring. The evidence is very uncertain about the effect of frequent monitoring of GRV on mortality rate (RR 0.91, 95% CI 0.60 to 1.37; I² = 8%; very low-certainty evidence), incidence of pneumonia (RR 1.08, 95% CI 0.64 to 1.83; heterogeneity not applicable; very low-certainty evidence), length of hospital stay (MD 2.00 days, 95% CI -2.15 to 6.15; heterogeneity not applicable; very low-certainty evidence), and incidence of vomiting (RR 0.14, 95% CI 0.02 to 1.09; heterogeneity not applicable; very low-certainty evidence). Two studies (500 participants) compared no GRV monitoring with frequent (12 hours or less) monitoring. Similarly, the evidence is very uncertain about the effect of no monitoring of GRV on mortality rate (RR 0.87, 95% CI 0.62 to 1.23; I² = 51%; very low-certainty evidence), incidence of pneumonia (RR 0.70, 95% CI 0.43 to 1.13; heterogeneity not applicable; very low-certainty evidence), length of hospital stay (MD -1.53 days, 95% CI -4.47 to 1.40; I² = 0%; very low-certainty evidence), and incidence of vomiting (RR 1.47, 95% CI 1.13 to 1.93; I² = 0%; very low-certainty evidence). One study (322 participants) assessed the impact of GRV threshold (500 mL per six hours) on clinical outcomes. The evidence is very uncertain about the effect of the threshold for GRV at time of aspiration on mortality rate (RR 1.01, 95% CI 0.74 to 1.38; heterogeneity not applicable; very low-certainty evidence), incidence of pneumonia (RR 1.03, 95% CI 0.72 to 1.46; heterogeneity not applicable; very low-certainty evidence), and length of hospital stay (MD -0.90 days, 95% CI -2.60 to 4.40; heterogeneity not applicable; very low-certainty evidence). Two studies (140 participants) explored the effects of returning or discarding the aspirated/drained GRV. The evidence is uncertain about the effect of discarding or returning the aspirated/drained GRV on the incidence of vomiting (RR 1.00, 95% CI 0.06 to 15.63; heterogeneity not applicable; very low-certainty evidence) and volume aspirated from the stomach (MD -7.30 mL, 95% CI -26.67 to 12.06, I² = 0%; very low-certainty evidence) We found no studies comparing the effects of protocol-based EN strategies that included GRV-related criteria against strategies that did not include such criteria. Authors' conclusions The evidence is very uncertain about the effect of GRV on clinical outcomes including mortality, pneumonia, vomiting, and length of hospital stay.
- Published
- 2021
17. The accuracy of Japanese administrative data in identifying acute exacerbation of idiopathic pulmonary fibrosis
- Author
-
Yuki Kataoka, Hiroyuki Ito, Tomoo Kishaba, Kazunori Tobino, Yosuke Yamamoto, Minoru Inomata, Takeshi Johkoh, Kazuya Ichikado, Takahito Nakamura, Keisuke Anan, Ryo Tachikawa, Kiminori Fujimoto, and Kodai Kawamura
- Subjects
Pulmonary and Respiratory Medicine ,medicine.medical_specialty ,Validation study ,Exacerbation ,business.industry ,Target population ,Disease ,medicine.disease ,Predictive value ,Confidence interval ,Idiopathic pulmonary fibrosis ,Chart review ,Internal medicine ,medicine ,Pediatrics, Perinatology, and Child Health ,business - Abstract
BackgroundThis study aimed to develop criteria for identifying patients with acute exacerbation of idiopathic pulmonary fibrosis (AE-IPF) from Japanese administrative data and validate the pre-existing criteria.MethodsThis retrospective, multi-center validation study was conducted at eight institutes in Japan to verify the diagnostic accuracy of the disease name for AE-IPF. We used the Japanese Diagnosis Procedure Combination data to identify patients with a disease name that could meet the diagnostic criteria for AE-IPF, who were admitted to the eight institutes from January 2016 to February 2019. As a reference standard, two respiratory physicians performed a chart review to determine whether the patients had a disease that met the diagnostic criteria for AE-IPF. Furthermore, two radiologists interpreted the chest computed tomography findings of cases considered AE-IPF and confirmed the diagnosis. We calculated the positive predictive value (PPV) for each disease name and its combination.ResultsWe included 830 patients; among them, 216 were diagnosed with AE-IPF through the chart review. We combined the groups of disease names and yielded two criteria: the criteria with the highest PPV (0.72 [95% confidence interval 0.62 to 0.81]) and that with a slightly less PPV (0.61 [0.53 to 0.68]) but more true positives. Pre-existing criteria showed a PPV of 0.40 (0.31 to 0.49).ConclusionThe criteria derived in this study for identifying AE-IPF from Japanese administrative data show a fair PPV. Although these criteria should be carefully interpreted according to the target population, our findings could be utilized in future database studies on AE-IPF.
- Published
- 2021
18. Impact on prognosis of rebiopsy in advanced non-small cell lung cancer patients after epidermal growth factor receptor-tyrosine kinase inhibitor treatment: a systematic review
- Author
-
Takuma Imakita, Hirotaka Matsumoto, Yuki Kataoka, Katsuya Hirano, Toshiyuki Morisawa, and Azusa Sakurai
- Subjects
0301 basic medicine ,Oncology ,Cancer Research ,medicine.medical_specialty ,Lung Neoplasms ,Biopsy ,Antineoplastic Agents ,lcsh:RC254-282 ,Piperazines ,03 medical and health sciences ,T790M ,0302 clinical medicine ,Non-small cell lung cancer ,Surgical oncology ,Carcinoma, Non-Small-Cell Lung ,Internal medicine ,Genetics ,Humans ,Medicine ,Osimertinib ,Lung cancer ,Adverse effect ,Protein Kinase Inhibitors ,Acrylamides ,Aniline Compounds ,business.industry ,Standard treatment ,Cancer ,Prognosis ,medicine.disease ,lcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogens ,Survival Analysis ,respiratory tract diseases ,ErbB Receptors ,Clinical trial ,030104 developmental biology ,Drug Resistance, Neoplasm ,Epidermal growth factor receptor-tyrosine kinase inhibitor ,T790M mutation ,030220 oncology & carcinogenesis ,Mutation ,Disease Progression ,Rebiopsy ,business ,Research Article - Abstract
Background Osimertinib, the third-generation epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI), has become the standard treatment in cases where rebiopsy reveals T790M mutation after the first-line EGFR-TKI treatment. However, the prognosis of patients after rebiopsy, the most important outcome for cancer patients, has not been described sufficiently. This systematic review aimed to clarify whether rebiopsy contributes to improved prognosis in the first- or second-generation EGFR-TKI refractory patients. Methods Using free word and control terms related to “non-small cell lung cancer” and “rebiopsy,” we searched studies from Medical Literature Analysis and Retrieval System Online via PubMed, Embase, Cochrane Central Register of Controlled Trials, and World Health Organization International Clinical Trials Registry Platform. We included cohort studies and case reports written in English and judged whether each study answers our research questions. Results Of the 144 studies included, only one reported the prognosis of patients with/without rebiopsy showing that in EGFR-TKI refractory non-small cell lung cancer patients, the post-progression survival (PPS) was significantly longer in patients who received rebiopsy and treatment based on a resistant mechanism (median PPS 24.2 months) than those who received rebiopsy and salvage regimen (median PPS 15.2 months, p = 0.002) and who did not receive rebiopsy (median PPS 9.7 months, p
- Published
- 2019
19. Effectiveness of empirical anti-pseudomonal antibiotics in patients with recurrent COPD exacerbation: A multicenter retrospective cohort study
- Author
-
Akihiro Shiroshita, Shunta Tsutsumi, Yuki Kataoka, Keisuke Tomii, Masahiro Ohgiya, Hiroshi Shiba, Shinya Matsushita, Chisato Miyakoshi, Chigusa Shirakawa, Yuya Kimura, and Kenya Sato
- Subjects
medicine.medical_specialty ,business.industry ,medicine.drug_class ,Copd exacerbation ,Internal medicine ,Antibiotics ,medicine ,In patient ,Retrospective cohort study ,business - Abstract
Background: Although frequent chronic obstructive pulmonary disease (COPD) exacerbation has been associated with the isolation of Pseudomonas aeruginosa (PA) in sputum cultures, it remains unknown whether the empirical use of anti-pseudomonal antibiotics can improve outcomes in patients with frequent COPD exacerbations. Research Question: Does empirical use of anti-pseudomonal antibiotics improve the length of the hospital stay in patients with recurrent COPD exacerbation?Study Design and Methods: This multicenter retrospective cohort study was conducted in seven hospitals in Japan. We included patients aged ≥40 years who were admitted to the hospital with COPD exacerbation more than twice during the study period (April 1, 2008 to July 31, 2020). The primary outcome was the length of the hospital stay. For statistical analysis, a log-linked Gamma model was used. Parameters were estimated using a generalized estimating equation model with an exchangeable correlation structure accounting for repeated observations from a single patient. Covariates included age, body mass index, home oxygen therapy use, respiratory rate, heart rate, oxygen use on admission, mental status, systemic steroid use, activities of daily living, and number of recurrences. Hospital-specific effects were specified as fixed effects.Results: Among 1573 patients with COPD exacerbation, 344 patients and 965 observations of recurrent COPD exacerbations were selected. Anti-pseudomonal antibiotics were used in 173 patients (18%). The estimated change in the length of the hospital stay between the anti-pseudomonal and non-anti-pseudomonal antibiotics groups was 0.044 days [95% confidence interval; -0.077, 0.166]. Interpretation: Use of empirical anti-pseudomonal antibiotics based only on recurrence may not be necessary. Further large-scale studies are needed to more precisely evaluate the effectiveness of empirical anti-pseudomonal antibiotics.
- Published
- 2021
20. Accuracy of Anti-GBM Antibodies in Diagnosing Anti-Glomerular Basement Membrane Disease: A Systematic Review and Meta-Analysis
- Author
-
Seiji Takenouchi, Yasuhiro Oda, Noboru Hagino, Akihiro Shiroshita, and Yuki Kataoka
- Subjects
medicine.medical_specialty ,medicine.diagnostic_test ,business.industry ,Anti-Glomerular Basement Membrane Disease ,MEDLINE ,Retrospective cohort study ,Disease ,Cochrane Library ,Sensitivity and Specificity ,Antibodies, Antineutrophil Cytoplasmic ,Clinical trial ,Nephrology ,Meta-analysis ,Internal medicine ,Biopsy ,medicine ,Humans ,business ,Publication Bias ,Cohort study - Abstract
Background: The sensitivity and specificity of anti-glomerular basement membrane (GBM) antibodies have not been systematically analyzed. In this systematic review, we aimed to evaluate the diagnostic accuracy of anti-GBM antibodies for anti-GBM disease. Summary: Potential studies were searched using MEDLINE, Embase, the Cochrane Library, and the International Clinical Trials Registry Platform based on the index test and target condition. The inclusion criteria were prospective or retrospective cohort studies or case-control studies assessing the sensitivity and specificity of anti-GBM antibodies, and the reference standard was clinical diagnosis including biopsy results. The exclusion criteria were review articles, case reports, animal studies, and in vitro studies. Quality assessment was conducted based on the Quality Assessment of Diagnostic Accuracy Studies-2. The pooled estimates of sensitivity and specificity were calculated using a bivariate random-effects model. The overall quality was evaluated using the Grades of Recommendation, Assessment, Development, and Evaluation. Six studies (1,691 patients) and 11 index tests were included in our systematic review. A high risk of bias and concerns regarding the applicability of patient selection were noted because of the case-control design in 67% of the included studies. The pooled sensitivity and specificity were 93% (95% CI: 84–97%) and 97% (95% CI: 94–99%), respectively. The certainty of evidence was low because of the high risk of bias and indirectness. Key Messages: Anti-GBM antibodies may exhibit high sensitivity and specificity in the diagnosis of anti-GBM disease. Further cohort studies are needed to confirm their precise diagnostic accuracy and compare diagnostic accuracies among different immunoassays.
- Published
- 2021
21. Heterogeneity in the diagnosis of plasmablastic lymphoma, plasmablastic myeloma, and plasmablastic neoplasm: a scoping review
- Author
-
Hirotaka Mori, Takayuki Ikezoe, Shunsuke Taito, Hiroshi Ohkawara, Masahiko Fukatsu, Yuka Oka, and Yuki Kataoka
- Subjects
medicine.medical_specialty ,Clinical Decision-Making ,Diagnosis, Differential ,Internal medicine ,medicine ,Biomarkers, Tumor ,Neoplasm ,Humans ,Neoplasms, Plasma Cell ,Neoplasm Staging ,Hematology ,business.industry ,Disease Management ,Diagnostic algorithms ,medicine.disease ,Plasmablastic Lymphoma ,Radiology ,Disease Susceptibility ,Differential diagnosis ,Neoplasm Grading ,Symptom Assessment ,business ,Multiple Myeloma ,Plasmablastic lymphoma ,Algorithms - Abstract
The diagnosis of plasmablastic lymphoma (PBL), plasmablastic myeloma (PBM), and plasmablastic neoplasm (PBN) may be arbitrary in some cases because these entities can be indistinct. We conducted this scoping review to investigate heterogeneity in diagnostic criteria used in previous studies and validate the diagnostic results of previous diagnostic algorithms and the algorithm we developed, which also includes diagnosis of PBN. Using the PRISMA Extension for Scoping Reviews, we analyzed literature published between September 2017 and April 2020. We identified a total of 163 cases (128 PBL, 32 PBM, and 3 PBN) from 77 case reports and 8 case series. We found that diagnostic criteria in the literature varied for PBL but were consistent for PBM. Our algorithm was the first attempt to include PBN in a complete structure. The results of the three diagnostic algorithms varied significantly. Hematologists and pathologists should pay more attention to the differential diagnosis of PBL, PBM, and PBN.
- Published
- 2021
22. Three comments on the methodology of a hypothermia study
- Author
-
Yuki Kataoka, Daisuke Kato, Kentaro Kinjo, Yuki Tachibana, Shin Yoshida, and Kazuoki Inoue
- Subjects
Medicine (General) ,R5-920 ,business.industry ,Anesthesia ,Internal Medicine ,Medicine ,Geriatrics and Gerontology ,Hypothermia ,medicine.symptom ,Family Practice ,business ,Letters to the Editor ,Letter to the Editor - Published
- 2021
23. Diagnostic accuracy of Aspergillus-specific antibodies for chronic pulmonary aspergillosis: A systematic review and meta-analysis
- Author
-
Shinji Okabayashi, Ho Namkoong, Keisuke Anan, Yuki Kataoka, Ryohei Yamamoto, and Yosuke Yamamoto
- Subjects
0301 basic medicine ,medicine.medical_specialty ,030106 microbiology ,Enzyme-Linked Immunosorbent Assay ,Dermatology ,Immunologic Tests ,Malignancy ,Aspergillosis ,Gastroenterology ,Sensitivity and Specificity ,030207 dermatology & venereal diseases ,03 medical and health sciences ,Immunocompromised Host ,0302 clinical medicine ,Internal medicine ,Medicine ,Antibodies, Fungal ,Aspergillus ,biology ,Receiver operating characteristic ,business.industry ,Diagnostic Tests, Routine ,Chronic pulmonary aspergillosis ,General Medicine ,medicine.disease ,Precipitin ,biology.organism_classification ,Infectious Diseases ,ROC Curve ,Meta-analysis ,Immunoglobulin G ,Chronic Disease ,biology.protein ,Pulmonary Aspergillosis ,Antibody ,business - Abstract
We performed this study to provide the latest evidence of the diagnostic accuracy of all Aspergillus antibodies for chronic pulmonary aspergillosis (CPA). In this meta-analysis, we searched the Cochrane Central Register of Controlled Trials, MEDLINE, Embase, and other databases, until 19 March 2020, for studies that examined the diagnostic accuracy of each Aspergillus-specific antibody for CPA and assessed the risk of bias using the revised Quality Assessment of Diagnostic Accuracy Studies-2 tool. We integrated the results using a hierarchical summary receiver operating characteristic (HSROC) model and calculated the point estimates of specificity with sensitivity fixed at 0.90 using the HSROC curve. We identified 32 published and one unpublished studies, including 75 studies on five antibody test types: 18 of precipitin test (2810 participants), 46 of IgG (8197), three of IgA (283), six of IgM (733) and two of combined IgG and IgM (IgG + IgM) (920). The results of specificity with sensitivity fixed at 0.90 were as follows: precipitin test, 0.93 (95% credible intervals: 0.86, 1.00); IgG, 0.90 (0.86, 0.95); IgA, 0.74 (0.00, 1.00); IgM, 0.50 (0.37, 0.53); IgG + IgM, 0.47 (0.00, 1.00). However, the precipitin test showed imprecision and instability in the sensitivity analysis. Most studies had a high risk of bias due to the case-control design. Although there is lack of applicability for malignancy or immunosuppressive patients, our study suggests a preference for IgG over other antibody tests in CPA screening. Particularly, IgG should be used as an adjunct when ruling out CPA.
- Published
- 2021
24. Does the order of busulfan and cyclophosphamide affect allogeneic stem cell transplantation related liver toxicity?
- Author
-
Yuki Kataoka, Yasutaka Kuniyoshi, and Keisuke Kidoguchi
- Subjects
medicine.medical_specialty ,Hematology ,Cyclophosphamide ,Liver toxicity ,business.industry ,Hematopoietic Stem Cell Transplantation ,General Medicine ,Pharmacology ,Transplantation ,Liver ,Internal medicine ,medicine ,Stem cell ,business ,Busulfan ,medicine.drug - Published
- 2021
25. Certolizumab pegol for maintenance of remission in Crohn’s disease
- Author
-
Taku Kobayashi, Hajime Yamazaki, Yuki Kataoka, Keisuke Anan, Yasushi Tsujimoto, Shinichiro Shinzaki, Ryohei Yamamoto, Shinji Okabayashi, Yusuke Honzawa, Norio Watanabe, and Katsuyoshi Matsuoka
- Subjects
medicine.medical_specialty ,Crohn's disease ,business.industry ,Internal medicine ,medicine ,Pharmacology (medical) ,Certolizumab pegol ,medicine.disease ,business ,Gastroenterology ,medicine.drug - Published
- 2020
26. Impact of steroid therapy on exacerbation of chronic obstructive pulmonary disease with community-onset pneumonia: a multicenter retrospective cohort study
- Author
-
Hiroshi Shiba, Kei Nakashima, Yu Tanaka, Chigusa Shirakawa, Yuki Kataoka, Akihiro Shiroshita, and Akihiro Nishi
- Subjects
medicine.medical_specialty ,COPD ,Exacerbation ,business.industry ,medicine.medical_treatment ,Tracheal intubation ,Confounding ,Retrospective cohort study ,Hypoxia (medical) ,medicine.disease ,Comorbidity ,respiratory tract diseases ,Pneumonia ,Internal medicine ,medicine ,medicine.symptom ,business - Abstract
Introduction: There is no consensus on steroid use in patients with exacerbation of chronic obstructive pulmonary disease (COPD) and pneumonia as a comorbidity. Aims and Objectives: The aim of this study was to evaluate the effectiveness of steroids for patients with COPD exacerbation and pneumonia. Methods: This multicenter retrospective observational study was performed at three acute general hospitals in Japan. We analyzed the association between parenteral or oral steroid therapy and the time to clinical stability in COPD exacerbation complicated by community-onset pneumonia. We included patients with COPD and pneumonia who were admitted to the three hospitals. We excluded patients who had other causes of hypoxia, those who required tracheal intubation or vasopressors on the day of admission, and those who were clinically stable on the day of admission. The primary outcome was the time to clinical stability. We calculated crude subdistribution hazard ratio (sHR) between steroid users and non-steroid users. In addition, we used the Fine–Gray model accounting for the competing risk of death with adjustment for potential confounders. Results: We included 1038 patients (mean age, 80.0 years; 938 [90.4%] male, 595 [57.3%] steroid users). The number of deaths in steroid users and non-steroid users were 41 (6.9%) and 25 (5.6%). The crude and adjusted sHR of the time to clinical stability in steroid users to that in non-steroid users was 3.1 (P = 0.08) and 0.93 (P = 0.40), respectively. Conclusions: Steroid therapy for COPD exacerbation with pneumonia could not significantly improve the time to clinical stability.
- Published
- 2020
27. COVID-19 randomized controlled trials in medRxiv and PubMed
- Author
-
Takashi Ariie, Yuki Kataoka, Toshi A. Furukawa, Yasushi Tsujimoto, and Shiho Oide
- Subjects
Research design ,2019-20 coronavirus outbreak ,medicine.medical_specialty ,PubMed ,Coronavirus disease 2019 (COVID-19) ,business.industry ,SARS-CoV-2 ,Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) ,MEDLINE ,COVID-19 ,030204 cardiovascular system & hematology ,law.invention ,03 medical and health sciences ,0302 clinical medicine ,Randomized controlled trial ,law ,Research Design ,Internal medicine ,Internal Medicine ,Medicine ,Humans ,030212 general & internal medicine ,business ,Letter to the Editor ,Randomized Controlled Trials as Topic - Abstract
Highlights • This study investigated the difference between COVID-19 RCT in medRxiv and in PubMed. • SPIN in the conclusion was more frequently seen in reports in medRxiv than PubMed. • Readers should pay attention to the overstatements in preprints of COVID-19 RCT.
- Published
- 2020
28. Efficacy and safety of the starting position during colonoscopy: a systematic review and meta-analysis
- Author
-
Daeho Park, Kazuoki Inoue, Eiichi Kakehi, Yuki Kataoka, Jun Watanabe, and Shizukiyo Ishikawa
- Subjects
medicine.medical_specialty ,Supine position ,medicine.diagnostic_test ,business.industry ,MEDLINE ,Colonoscopy ,Review ,Confidence interval ,law.invention ,Clinical trial ,Randomized controlled trial ,law ,Internal medicine ,Meta-analysis ,medicine ,Pharmacology (medical) ,lcsh:Diseases of the digestive system. Gastroenterology ,lcsh:RC799-869 ,Adverse effect ,business - Abstract
Background and study aims We aimed to assess the efficacy and safety of the starting position during colonoscopy. Patients and methods We searched CENTRAL, MEDLINE, EMBASE, and the WHO International Clinical Trials Registry Platform through February 2019 to identify studies reporting the comparison between the right/supine/prone/tilt-down and left lateral starting position during colonoscopy. The primary outcomes were mean cecal insertion time and adverse events requiring medication. Two reviewers performed study selection and risk of bias assessment. We determined the quality of evidence using the Grading of Recommendations, Assessment, Development, and Evaluation method. This study was registered in PROSPERO (CRD42019124360). Results We identified 10 randomized controlled trials (RCTs) (2083 participants), including three trials on right/tilt-down versus left, two trials on supine/prone versus left, respectively. Mean difference in mean cecal insertion time in supine versus left was –41.0 s (95 % confidence interval [CI] –57.3 to –24.7) in one study and in tilt-down versus left was – 37.3 s (95 % CI –72.1 to –2.4; I2 = 58 %) in three studies; however, there were no statistically significant differences in prone/right versus left position (very low certainty of evidence). Four of eight studies noted adverse effects requiring medication (moderate certainty of evidence). One RCT applying the tilt-down position was terminated because of increased occurrence of oxygen desaturation. Conclusion We could not conclusively determine the efficacy and safety of the starting position during colonoscopy because of low certainty of evidence. Further studies are needed to confirm the efficacy and safety of the starting potion during colonoscopy.
- Published
- 2020
29. Pharmacological interventions for preventing clotting of extracorporeal circuits during continuous renal replacement therapy
- Author
-
Sei Takahashi, Yasushi Tsujimoto, Yukihiko Nakata, Hiraku Tsujimoto, Yuki Kataoka, Mai Akazawa, and Tomoko Fujii
- Subjects
Catheter Obstruction ,medicine.medical_specialty ,Patient Dropouts ,Continuous Renal Replacement Therapy ,medicine.drug_class ,medicine.medical_treatment ,030232 urology & nephrology ,Low molecular weight heparin ,Hemorrhage ,Kidney ,Citric Acid ,03 medical and health sciences ,0302 clinical medicine ,Bias ,Internal medicine ,medicine ,Humans ,Pharmacology (medical) ,Renal replacement therapy ,Dosing ,Adverse effect ,Blood Coagulation ,Randomized Controlled Trials as Topic ,Heparin ,business.industry ,Anticoagulant ,Anticoagulants ,030208 emergency & critical care medicine ,Recovery of Function ,Acute Kidney Injury ,Heparin, Low-Molecular-Weight ,Thrombocytopenia ,Clinical trial ,Relative risk ,Meta-analysis ,business ,Filtration - Abstract
Background Acute kidney injury (AKI) is a major comorbidity in hospitalised patients. Patients with severe AKI require continuous renal replacement therapy (CRRT) when they are haemodynamically unstable. CRRT is prescribed assuming it is delivered over 24 hours. However, it is interrupted when the extracorporeal circuits clot and the replacement is required. The interruption may impair the solute clearance as it causes under dosing of CRRT. To prevent the circuit clotting, anticoagulation drugs are frequently used. Objectives To assess the benefits and harms of pharmacological interventions for preventing clotting in the extracorporeal circuits during CRRT. Search methods We searched the Cochrane Kidney and Transplant Register of Studies up to 12 September 2019 through contact with the Information Specialist using search terms relevant to this review. Studies in the Register are identified through searches of CENTRAL, MEDLINE, and EMBASE, conference proceedings, the International Clinical Trials Register (ICTRP) Search Portal and ClinicalTrials.gov. Selection criteria We selected randomised controlled trials (RCTs or cluster RCTs) and quasi-RCTs of pharmacological interventions to prevent clotting of extracorporeal circuits during CRRT. Data collection and analysis Data were abstracted and assessed independently by two authors. Dichotomous outcomes were calculated as risk ratio (RR) with 95% confidence intervals (CI). The primary review outcomes were major bleeding, successful prevention of clotting (no need of circuit change in the first 24 hours for any reason), and death. Evidence certainty was determined using the Grading of Recommendation Assessment, Development, and Evaluation (GRADE) approach. Main results A total of 34 completed studies (1960 participants) were included in this review. We identified seven ongoing studies which we plan to assess in a future update of this review. No included studies were free from risk of bias. We rated 30 studies for performance bias and detection bias as high risk of bias. We rated 18 studies for random sequence generation, six studies for the allocation concealment, three studies for performance bias, three studies for detection bias, nine studies for attrition bias, 14 studies for selective reporting and nine studies for the other potential source of bias, as having low risk of bias. We identified eight studies (581 participants) that compared citrate with unfractionated heparin (UFH). Compared to UFH, citrate probably reduces major bleeding (RR 0.22, 95% CI 0.08 to 0.62; moderate certainty evidence). Citrate may have little or no effect on death at 28 days (RR 1.06, 95% CI 0.86 to 1.30, moderate certainty evidence), while citrate versus UFH may have little or no effect on successful prevention of clotting (RR 1.01, 95% CI 0.77 to 1.32; moderate certainty evidence). Citrate versus UFH may reduce the number of participants who drop out of treatment due to adverse events (RR 0.47, 95% CI 0.15 to 1.49; low certainty evidence). Compared to UFH, citrate may make little or no difference to the recovery of kidney function (RR 0.95, 95% CI 0.66 to 1.36; low certainty evidence). Compared to UFH, citrate may reduce thrombocytopenia (RR 0.39, 95% CI 0.14 to 1.03; low certainty evidence). It was uncertain whether citrate reduces a cost to health care services because of inadequate data. For low molecular weight heparin (LMWH) versus UFH, six studies (250 participants) were identified. Compared to LMWH, UFH may reduce major bleeding (0.58, 95% CI 0.13 to 2.58; low certainty evidence). It is uncertain whether UFH versus LMWH reduces death at 28 days or leads to successful prevention of clotting. Compared to LMWH, UFH may reduce the number of patient dropouts from adverse events (RR 0.29, 95% CI 0.02 to 3.53; low certainty evidence). It was uncertain whether UFH versus LMWH leads to the recovery of kidney function because no included studies reported this outcome. It was uncertain whether UFH versus LMWH leads to thrombocytopenia. It was uncertain whether UFH reduces a cost to health care services because of inadequate data. For the comparison of UFH to no anticoagulation, one study (10 participants) was identified. It is uncertain whether UFH compare to no anticoagulation leads to more major bleeding. It is uncertain whether UFH improves successful prevention of clotting in the first 24 hours, death at 28 days, the number of patient dropouts due to adverse events, recovery of kidney function, thrombocytopenia, or cost to health care services because no study reported these outcomes. For the comparison of citrate to no anticoagulation, no completed study was identified. Authors' conclusions Currently, available evidence does not support the overall superiority of any anticoagulant to another. Compared to UFH, citrate probably reduces major bleeding and probably has little or no effect on preventing clotting or death at 28 days. For other pharmacological anticoagulation methods, there is no available data showing overall superiority to citrate or no pharmacological anticoagulation. Further studies are needed to identify patient populations in which CRRT should commence with no pharmacological anticoagulation or with citrate.
- Published
- 2020
30. National Prescription Patterns of Antidepressants in the Treatment of Adults With Major Depression in the US Between 1996 and 2015: A Population Representative Survey Based Analysis
- Author
-
Andrea Cipriani, Yan Luo, Edoardo G Ostinelli, Toshi A. Furukawa, and Yuki Kataoka
- Subjects
medicine.medical_specialty ,lcsh:RC435-571 ,Population ,03 medical and health sciences ,0302 clinical medicine ,lcsh:Psychiatry ,Internal medicine ,medicine ,Medical prescription ,suboptimal dose ,education ,Depression (differential diagnoses) ,Original Research ,Psychiatry ,prescription ,Sertraline ,education.field_of_study ,Fluoxetine ,antidepressant ,major depressive disorder ,business.industry ,medicine.disease ,030227 psychiatry ,Psychiatry and Mental health ,trend ,Major depressive disorder ,Antidepressant ,Medical Expenditure Panel Survey ,business ,030217 neurology & neurosurgery ,medicine.drug - Abstract
Few studies have delineated the real-world, long-term trends of prescription patterns of antidepressants for patients with major depressive disorder (MDD). This study aims to describe their vicissitudes in the nationally representative sample of the US from 1996 to 2015 and explore their characteristics. We used the Medical Expenditure Panel Survey, a nationally representative database of the US population, between 1996 and 2015. We estimated the prevalence of MDD among adults, calculated the proportions of those on antidepressant treatment as well as those on specific drugs through the two decades, and determined their dosages in 2015. We conducted multivariable regression to find possible factors related to their suboptimal prescriptions. The prevalence of adults diagnosed with MDD increased from 6.1% (95% CI, 5.7–6.6%) in 1996 to 10.4% (9.7–11.1%) in 2015. The proportion of patients without any antidepressant therapy decreased but still accounted for 30.6% (28.3–33.1%) in 2015. Sertraline and fluoxetine were among the most frequently prescribed antidepressants throughout the 20 years, while the trend for some new drugs changed dramatically. 16.1% (12.5–20.2%) of patients of MDD on antidepressant monotherapy were prescribed with suboptimal doses in 2015; the risk was lower for those who had higher Body Mass Index (OR 0.94 [0.90–0.99]), longer-term prescriptions (OR 0.92 [0.87–0.97]), and the risk was higher for those who were prescribed with tricyclic antidepressants (OR 11.21 [2.12–59.34], compared with serotonin reuptake inhibitors (SSRIs)), and antidepressants other than SSRIs and serotonin and norepinephrine reuptake inhibitors (OR 4.12 [1.95, 8.73], compared with SSRIs). This study confirmed the growing numbers of patients with MDD and the increase in the antidepressant prescriptions among them. However, the existence of patients without any antidepressant prescriptions or with suboptimal prescriptions and the variable prescription patterns through the decades might suggest some unresolved gaps between evidence and practice.
- Published
- 2020
31. High versus low blood pressure targets for cardiac surgery with cardiopulmonary bypass
- Author
-
Junji Kumasawa, Yuki Kataoka, Joey Sw Kwong, Yuki Kotani, Takuo Yoshida, Junichi Izawa, and Shoko Fujioka
- Subjects
medicine.medical_specialty ,Blood pressure ,law ,business.industry ,Internal medicine ,Cardiology ,medicine ,Cardiopulmonary bypass ,Pharmacology (medical) ,business ,Cardiac surgery ,law.invention - Published
- 2019
32. Efficacy and safety of nivolumab in previously treated patients with non-small cell lung cancer: A multicenter retrospective cohort study
- Author
-
Mitsunori Morita, Takehiro Yasuda, Satoshi Hara, Naoki Sakai, Keisuke Tomii, Motonari Fukui, Yasushi Fukuda, Toyohiro Hirai, Masataka Hirabayashi, Manabu Ishitoko, Tadashi Ishida, Moon Hee Hwang, Hitoshi Nakaji, Takakazu Sugita, Yuki Kataoka, Hiroshige Yoshioka, Takeshi Morimoto, Tadashi Mio, Daichi Fujimoto, and Young Hak Kim
- Subjects
Male ,0301 basic medicine ,Pulmonary and Respiratory Medicine ,Oncology ,Cancer Research ,medicine.medical_specialty ,Lung Neoplasms ,Multivariate analysis ,Drug-Related Side Effects and Adverse Reactions ,Cohort Studies ,03 medical and health sciences ,Antineoplastic Agents, Immunological ,0302 clinical medicine ,Carcinoma, Non-Small-Cell Lung ,Internal medicine ,medicine ,Humans ,Adverse effect ,Lung cancer ,Aged ,Retrospective Studies ,Pneumonitis ,business.industry ,Retrospective cohort study ,Pneumonia ,Middle Aged ,medicine.disease ,Survival Analysis ,ErbB Receptors ,Clinical trial ,Nivolumab ,030104 developmental biology ,030220 oncology & carcinogenesis ,Female ,Observational study ,business - Abstract
Introduction Nivolumab has been shown to be effective and safe in previously treated patients with advanced non-small cell lung cancer (NSCLC). However, little is known regarding its performance in real-world (i.e., non-trial) settings. Furthermore, nivolumab efficacy is unknown in patients who are ineligible for clinical trials or who are categorized into small subgroups in such trials. Methods We conducted a 15-center, observational, retrospective cohort study of patients with advanced NSCLC who received nivolumab monotherapy between January and December 2016. Results Of 613 patients included in our study, 141 had poor performance status (PS) and 106 were EGFR mutation – or ALK rearrangement-positive. The response and disease control rates were 20% and 44%, respectively; the estimated 1-year progression-free survival (PFS) was 18%. Multivariate analysis identified never smoking, poor PS, and EGFR mutation/ALK rearrangement as independent negative predictors of PFS. The most frequently reported grade ≥3 adverse event was pneumonitis (5% of patients). Severe pneumonitis (grade ≥3) occurred significantly earlier than mild pneumonitis (1.6 vs. 2.3 months, P = 0.031). Patients with pneumonitis achieved higher response rates and longer PFS than those without (37% vs. 18%, and 5.8 vs. 2.1 months, respectively; P = 0.002). Conclusions Smoking status, PS, and EGFR mutation/ALK rearrangement were independent predictors of PFS. Our study elucidated nivolumab's efficacy in previously underreported patient populations; i.e., those with poor PS and/or with driver oncogenes. We also found that pneumonitis is not infrequent, and carries key implications for outcomes. These data should be useful for improving the clinical courses of nivolumab-treated patients with NSCLC.
- Published
- 2018
33. Possibility of Interstitial Lung Disease as a Phlebosclerotic Colitis Manifestation
- Author
-
Tomoyasu Takemura, Mitsunori Kanagaki, Yuki Kataoka, Yoshitomo Yasumizu, Reika Iki, Yasuyuki Nishioka, and Naoko Matsubara
- Subjects
medicine.medical_specialty ,Exacerbation ,medicine.diagnostic_test ,business.industry ,Single Case ,Phlebosclerotic colitis ,Gastroenterology ,Chest ct ,Interstitial lung disease ,Colonoscopy ,Disease ,respiratory system ,medicine.disease ,Mesenteric Vein ,Mesenteric phlebosclerosis ,Internal medicine ,Medicine ,lcsh:Diseases of the digestive system. Gastroenterology ,lcsh:RC799-869 ,Colitis ,business ,Calcification - Abstract
Phlebosclerotic colitis presents with ischemic bowels and calcification of the mesenteric veins. Owing to its rarity, we have little information on the complications of this disease. Herein, we report on a 77-year-old woman with phlebosclerotic colitis and interstitial lung disease. She was diagnosed as having phlebosclerotic colitis by CT and colonoscopy. At the same time, chest CT also showed interstitial lung disease. After 4 years, she experienced exacerbation of interstitial lung disease. She recovered without treatment. The occurrence of interstitial lung disease may have been associated with her phlebosclerotic colitis.
- Published
- 2018
34. Insufficient comprehensiveness of study collection and leaping to the conclusion
- Author
-
Yuki Kataoka, Yuki Honda, Keita Morikawa, Toshinori Nishizawa, Hideki Tsunoda, and Tomohisa Oku
- Subjects
Medicine (General) ,R5-920 ,Nursing ,business.industry ,Internal Medicine ,Medicine ,Geriatrics and Gerontology ,Letters to the Editor ,Family Practice ,business ,Letter to the Editor - Published
- 2021
35. P30-10 Prevention of chemotherapy-induced peripheral neuropathy by compression therapy
- Author
-
Masakazu Toi, Eiji Suzuki, Nobuko Kawaguchi, Takahumi Ikeda, Yuki Kataoka, Shigeru Tsuyuki, and Satoshi Morita
- Subjects
Oncology ,medicine.medical_specialty ,Chemotherapy-induced peripheral neuropathy ,business.industry ,Internal medicine ,medicine ,Hematology ,Compression therapy ,business - Published
- 2021
36. Accuracy of Ultrasound for Evaluation of Colorectal Segments in Patients With Inflammatory Bowel Diseases: A Systematic Review and Meta-analysis
- Author
-
Reiko Kunisaki, Toshifumi Hibi, Mariangela Allocca, Yusuke Miyatani, Manabu Shiraki, Kenji Kinoshita, Toshihiko Takada, Shinji Okabayashi, Taku Kobayashi, Yuki Kataoka, Shintaro Sagami, Hajime Yamazaki, and Pradeep Kakkadasam Ramaswamy
- Subjects
medicine.medical_specialty ,Colonoscopy ,Rectum ,Sensitivity and Specificity ,Inflammatory bowel disease ,Gastroenterology ,Crohn Disease ,Internal medicine ,medicine ,Humans ,Ultrasonography ,Crohn's disease ,Hepatology ,medicine.diagnostic_test ,business.industry ,Ultrasound ,Odds ratio ,Inflammatory Bowel Diseases ,medicine.disease ,Ulcerative colitis ,digestive system diseases ,medicine.anatomical_structure ,Meta-analysis ,Colitis, Ulcerative ,Colorectal Neoplasms ,business - Abstract
Background & Aims The accuracy of ultrasound for evaluation of individual colorectal segments in patients with inflammatory bowel diseases (IBD) has not been evaluated in a systematic review. We evaluated the diagnostic accuracy of ultrasound in different colorectal segments of patients with IBD. Methods We searched publication databases from inception through March 2019 for studies that assessed the accuracy of ultrasound in detection of inflammation in right, transverse, and left colon and in rectum in patients with IBD, using findings from colonoscopy as the reference standard. Subgroup analyses were performed including IBD type, patient age, body mass index, and study design. The risk of bias was assessed with the Quality Assessment of Diagnostic Accuracy Studies-2 tool. Results Nineteen studies (1101 patients) were included in the qualitative synthesis. After we assessed the risk of bias, 7 studies (comprising 84 patients with Crohn’s disease and 420 patients with ulcerative colitis) were included in the meta-analysis. Bowel wall thickness ≥ 3 mm identified colorectal segments with inflammation with 86.4% pooled sensitivity (95% CI, 76.1%–92.7%) and 88.3% pooled specificity (95% CI, 58.1%–97.6%). In rectum only, bowel wall thickness ≥ 3 mm identified inflammation with 74.5% sensitivity (95% CI, 53.0%–88.3%) and 69.5% specificity (95% CI, 33.6%–91.1%). Diagnostic accuracy was comparable among subgroups. Increased bowel wall flow and loss of stratification had higher true-positive odds ratios. Conclusions Based on meta-analysis of patient-level data, ultrasound has higher diagnostic accuracy for detecting inflammation in colon than rectum in patients with IBD. Studies are needed to increase the accuracy of ultrasound detection of inflammation in rectum.
- Published
- 2021
37. Acute onset collagenous colitis associated with protein‐losing enteropathy
- Author
-
Shuhei Yamamoto, Satoru Kitamura, Takahito Omae, Kosho Takasu, Yuki Kataoka, Sawako Kaku Hosokawa, Yuki Yoshimatsu, Masataka Hirabayashi, and Yuichiro Nakaya
- Subjects
medicine.medical_specialty ,Nausea ,aspirin ,Lansoprazole ,Case Report ,Case Reports ,acute onset ,Gastroenterology ,03 medical and health sciences ,0302 clinical medicine ,Internal medicine ,Internal Medicine ,medicine ,Enteropathy ,Aspirin ,Collagenous colitis ,business.industry ,Protein losing enteropathy ,protein‐losing enteropathy ,medicine.disease ,lansoprazole ,Small intestine ,collagenous colitis ,Diarrhea ,medicine.anatomical_structure ,030220 oncology & carcinogenesis ,030211 gastroenterology & hepatology ,Geriatrics and Gerontology ,medicine.symptom ,Family Practice ,business ,medicine.drug - Abstract
Collagenous colitis is a cause of chronic diarrhea. We report an atypical case of collagenous colitis, presenting with an acute onset, and associated with protein‐losing enteropathy. An 82‐year‐old woman was admitted with a 1 week history of nausea, appetite loss, and diarrhea. Serum albumin level was low. Protein leakage from the small intestine was found by a Technetium‐99m human serum albumin scintigraphy. We diagnosed the patient with collagenous colitis from pathology findings of multiple biopsies taken from the colon. This case implies that collagenous colitis should be considered in acute watery diarrhea, and that it can cause protein‐losing enteropathy.
- Published
- 2017
38. Patient gender as a factor associated with lymph node metastasis in T1 colorectal cancer: A systematic review and meta-analysis
- Author
-
Shingo Matsudaira, Takemasa Hayashi, Atsushi Katagiri, Yui Kimura, Yuichi Mori, Kunihiko Wakamura, Masashi Misawa, Katsuro Ichimasa, Toyoki Kudo, Yuki Kataoka, Toshiyuki Baba, Shin-ei Kudo, Hideyuki Miyachi, Fumio Ishida, Yuta Kouyama, and Tomokazu Hisayuki
- Subjects
Oncology ,Cancer Research ,medicine.medical_specialty ,Colorectal cancer ,business.industry ,Articles ,Odds ratio ,Publication bias ,medicine.disease ,Confidence interval ,03 medical and health sciences ,0302 clinical medicine ,medicine.anatomical_structure ,030220 oncology & carcinogenesis ,Meta-analysis ,Relative risk ,Internal medicine ,medicine ,030211 gastroenterology & hepatology ,business ,Grading (tumors) ,Lymph node - Abstract
Approximately 10% of patients with T1 colorectal cancer have lymph node metastases (LNM), requiring node dissection along with surgical resection. Patient gender was recently reported to affect the occurrence of LNM. The aim of the present study was to assess whether patient gender was predictive of LNM in T1 colorectal cancer. Public databases, including PubMed, EMBASE and the Cochrane Central Register of Controlled Trials were searched, using key terms related to ‘T1 colorectal cancer’ and ‘lymph node’. All relevant studies reporting the adjusted odds ratio or risk ratio of LNM in relation to patient gender were included. The quality of the studies was classified according to the Quality in Prognostic Studies tool. A random-effects model was used and the quality of the evidence was evaluated using the Grading of Recommendations Assessment, Development and Evaluation approach. The initial database search identified 2,492 publications; of those, 36 studies reported unadjusted results. Of the 36 studies, 4 reported adjusted results and fulfilled the inclusion criteria for this meta-analysis: 3 studies were graded as having a moderate risk of bias, and 1 had a low risk of bias. The present meta-analysis demonstrated that female gender was associated with increased risk of LNM (risk ratio=2.45, 95% confidence interval: 1.03–3.88). The I2 statistic was 0.901, classified as very low (+OOO) and was downgraded by the risk of bias, inconsistency and publication bias. In conclusion, female gender was found to be correlated with LNM in patients with T1 colorectal cancer.
- Published
- 2017
39. Publication statuses of clinical trials supporting FDA-approved immune checkpoint inhibitors: a meta-epidemiological investigation
- Author
-
Yasushi Tsujimoto, Yuki Kataoka, Yusuke Tsutsumi, Yosuke Yamamoto, Shunichi Fukuhara, Toshi A. Furukawa, and Kenji Omae
- Subjects
Drug ,Cancer Research ,medicine.medical_specialty ,Immune checkpoint inhibitors ,media_common.quotation_subject ,Antineoplastic Agents ,lcsh:RC254-282 ,Anticancer drugs ,03 medical and health sciences ,Clinical trials ,0302 clinical medicine ,Neoplasms ,Internal medicine ,Epidemiology ,Drug approval ,Genetics ,Humans ,Immunologic Factors ,Medicine ,030212 general & internal medicine ,Proportional Hazards Models ,media_common ,Clinical Trials as Topic ,Proportional hazards model ,business.industry ,Publications ,Hazard ratio ,Significant difference ,Journalism, Medical ,United states food and drug administration ,lcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogens ,United States ,Confidence interval ,Clinical trial ,Epidemiologic Studies ,Logistic Models ,Treatment Outcome ,Oncology ,030220 oncology & carcinogenesis ,business ,Publication Bias ,Follow-Up Studies ,Research Article - Abstract
Background The low data publication rate for Food and Drug Administration (FDA)-approved drugs, and discrepancies between FDA-submitted versus published data, remain a concern. We investigated the publication statuses of sponsor-submitted clinical trials supporting recent anticancer drugs approved by the FDA, with a focus on immune checkpoint inhibitors (ICPis). Methods We identified all ICPis approved between 2011 and 2014, thereby obtaining 3 years of follow-up data. We assessed the clinical trials performed for each drug indication and matched each trial with publications in the literature. The primary benchmark was the publication status 2 years post-approval. We examined the association between time to publication and drug type using a multilevel Cox regression model that was adjusted for clustering within drug indications and individual covariates. Results Between 2011 and 2014, 36 anticancer drugs including 3 ICPis were newly approved by the FDA. Of 19 trials investigating the 3 ICPis, 11 (58%) were published within 2 years post-approval. We randomly selected 10 of the 33 remaining anticancer drugs; 68 of 101 trials investigating these drugs (67%) were published. Overall, the publication rate was 66% at 2 years post-approval with a median time to publication of 2.3 years. There was no significant difference in the time to trial publication between ICPis and other anticancer drugs (adjusted hazard ratio [HR], 1.1; 95% confidence interval [CI], 0.8–1.7; P = 0.55). However, findings related to non-ICPis investigated specifically in randomized phase 2 or phase 3 trials were significantly more likely to be published earlier than those related to ICPis (adjusted HR, 7.4; 95% CI, 1.8–29.5; P = 0.005). Conclusion One in 3 sponsor-submitted trials of the most recently approved anticancer drugs remained unpublished 2 years post-FDA approval. We found no evidence that the drug type was associated with the time to overall trial publication.
- Published
- 2019
40. Certolizumab pegol for induction of remission in Crohn's disease
- Author
-
Hajime Yamazaki, Yuki Kataoka, Minoru Matsuura, Taku Kobayashi, Ryuhei So, Shinji Okabayashi, Norio Watanabe, Yasushi Tsujimoto, Shinichiro Shinzaki, Toshi A. Furukawa, and Katsuyoshi Matsuoka
- Subjects
Medicine General & Introductory Medical Sciences ,medicine.medical_specialty ,genetic structures ,education ,Placebo ,Antibodies, Monoclonal, Humanized ,law.invention ,03 medical and health sciences ,0302 clinical medicine ,Randomized controlled trial ,Crohn Disease ,law ,Internal medicine ,medicine ,Humans ,Immunologic Factors ,Pharmacology (medical) ,030212 general & internal medicine ,Certolizumab pegol ,Adverse effect ,Randomized Controlled Trials as Topic ,Crohn's disease ,business.industry ,Remission Induction ,Induction chemotherapy ,Induction Chemotherapy ,medicine.disease ,Confidence interval ,Relative risk ,Certolizumab Pegol ,030211 gastroenterology & hepatology ,business ,medicine.drug - Abstract
Background Crohn's disease (CD) is a chronic inflammatory disease of the gastrointestinal tract, and immune response modulation is the main treatment strategy to induce remission in active CD. Certolizumab pegol (CZP) is a tumor necrosis factor-alfa (TNF-α) inhibitor which regulates impaired immune response. Objectives The primary objectives were to evaluate the efficacy and safety of CZP for the induction of remission in CD. Search methods We searched MEDLINE, Embase, CENTRAL, the Cochrane IBD group specialized register, trials registers and other sources from inception to 28 January 2019. Moreover, we contacted the pharmaceutical company that manufactures CZP. Selection criteria We included randomized controlled trials comparing CZP with placebo or no treatment in active CD patients. Data collection and analysis We used standard Cochrane methodological procedures. The main outcomes selected for GRADE analysis were clinical remission at week 8 (Crohn's Disease Activity Index [CDAI] ≤150), clinical response at week 8 (CDAI reduction ≥ 100 or clinical remission), and serious adverse events. The Mantel-Haenszel random-effects method was applied for the statistical analyses. For dichotomous outcomes, we calculated the risk ratio (RR) and corresponding 95% confidence interval (95% CI). Main results Four studies involving 1485 participants with moderate to severe CD met the inclusion criteria and were used in the meta-analyses. All studies included active CD patients with CDAI ranging from 220 to 450. Most patients were adults over 18 years of age. One study was identified as high risk of bias due to a non-identical placebo while the other studies were judged to be at low risk of bias.CZP (100 mg to 400 mg every 2 to 4 weeks) was shown to be superior to placebo for achieving clinical remission at week 8 (RR 1.36, 95% CI 1.11 to 1.66; moderate certainty evidence). The raw numbers of participants achieving clinical remission at week 8 were 26.9% (225/835) and 19.8% (129/650) in the CZP and the placebo groups, respectively.CZP was shown to be superior to placebo for achieving clinical response at week 8 (RR 1.29, 95% CI 1.09 to 1.53; moderate certainty evidence). In raw numbers, clinical response at week 8 was achieved in 40.2% (336/835) and 30.9% (201/650) of participants in the CZP and the placebo groups, respectively.In raw numbers, serious adverse events were observed in 8.7% (73/835) and 6.2% (40/650) of participants in the CZP and the placebo groups, respectively (RR 1.35, 95% CI 0.93 to 1.97; moderate certainty evidence). Serious adverse events included worsening Crohn's disease, infections, and malignancy. Authors' conclusions Moderate certainty evidence suggests that CZP is effective for induction of clinical remission and clinical response in participants with active CD patients. It is uncertain whether the risk of serious adverse events differs between CZP and placebo as the 95% CI includes the possibility of a small decrease or doubling of events. Future studies are needed to evaluate the long-term efficacy and safety of CZP in CD patients.
- Published
- 2019
41. Additive Duloxetine for Cancer-Related Neuropathic Pain Nonresponsive or Intolerant to Opioid-Pregabalin Therapy: A Randomized Controlled Trial (JORTC-PAL08)
- Author
-
K. Sakai, Satoru Iwase, Yuki Kataoka, Takashi Kawaguchi, Atsuko Koyama, Hiroaki Tsukuura, Yoshihisa Matsumoto, Eriko Satomi, Masatomo Otsuka, Toshiaki Shinomiya, Hiroto Ishiki, Keisuke Ariyoshi, Takuhiro Yamaguchi, Yoshikazu Hasegawa, Tatsuya Morita, Hideaki Hasuo, Hiromichi Matsuoka, Yoichi Ohtake, Shunsuke Oyamada, Akihiro Tokoro, Hiroko Sakuma, Yoshinobu Matsuda, Hiroyuki Otani, and Tempei Miyaji
- Subjects
Male ,medicine.medical_specialty ,Palliative care ,Pregabalin ,Placebo ,Duloxetine Hydrochloride ,law.invention ,03 medical and health sciences ,chemistry.chemical_compound ,0302 clinical medicine ,Randomized controlled trial ,Double-Blind Method ,Japan ,law ,Internal medicine ,Clinical endpoint ,Medicine ,Duloxetine ,Humans ,030212 general & internal medicine ,Brief Pain Inventory ,General Nursing ,Aged ,Pain Measurement ,business.industry ,Cancer Pain ,Middle Aged ,Analgesics, Opioid ,Anesthesiology and Pain Medicine ,Treatment Outcome ,chemistry ,030220 oncology & carcinogenesis ,Neuropathic pain ,Neuralgia ,Drug Therapy, Combination ,Female ,Neurology (clinical) ,business ,medicine.drug - Abstract
Context Although opioids and pregabalin are widely used for cancer-related neuropathic pain (CNP), no clinical trials exist to determine which medications are effective when an opioid-pregabalin combination therapy fails. Objectives We investigated the efficacy of duloxetine for CNP nonresponsive or intolerant to opioid-pregabalin combination therapy. Methods A multicenter, randomized, double-blind, placebo-controlled trial was performed at 12 specialized palliative care services in Japan. Patients with CNP average pain scores (Brief Pain Inventory [BPI]–Item 5) ≥ 4 in the previous 24 hours and nonresponsive or intolerant to opioid-pregabalin combination therapy were eligible. Patients with chemotherapy-induced peripheral neuropathies were excluded. Patients were administered duloxetine 20 mg/day titrated to 40 mg/day or placebo for 10 days. The primary endpoint was BPI-Item 5 on Day 10. Responder analysis measured proportions of patients with 30% and 50% pain decreases. Results Seventy patients were enrolled. Complete case analysis revealed mean BPI-Item 5 on Day 10 of 4.03 for Group D vs. 4.88 for Group P (P = 0.053). Baseline observation carried forward analysis revealed mean BPI-Item 5 on Day 10 of 4.06 and 4.91 for Groups D and P, respectively (P = 0.048). Clinically meaningful pain improvement (≥30%) was reported by 44.1% (n = 15) of patients in Group D vs. 18.2% (n = 6) in Group P (P = 0.02); 32.4% (n = 11) vs. 3.0% (n = 1) of patients in Groups D and P, respectively, reported pain reduction ≥ 50% (P = 0.002). Conclusion Adding duloxetine to opioid-pregabalin therapy might have clinical benefit in alleviating refractory CNP. Further studies are needed to conclude the efficacy of adding duloxetine.
- Published
- 2019
42. External validation of pooled cohort equations using systolic blood pressure intervention trial data
- Author
-
Yuki Kataoka, Tadashi Miyamoto, Chisato Miyakoshi, Takashi Kuragaichi, and Yukihito Sato
- Subjects
0301 basic medicine ,Male ,medicine.medical_specialty ,Systole ,lcsh:Medicine ,Blood Pressure ,General Biochemistry, Genetics and Molecular Biology ,Cohort Studies ,03 medical and health sciences ,0302 clinical medicine ,Risk Factors ,Internal medicine ,Discrimination ,medicine ,Humans ,030212 general & internal medicine ,Intervention trial ,lcsh:Science (General) ,lcsh:QH301-705.5 ,business.industry ,lcsh:R ,External validation ,Area under the curve ,General Medicine ,Middle Aged ,Atherosclerosis ,Statin therapy ,Confidence interval ,Research Note ,030104 developmental biology ,Blood pressure ,lcsh:Biology (General) ,Sprint ,Cohort ,Calibration ,Female ,Pooled cohort equations ,business ,lcsh:Q1-390 - Abstract
Objective The risk of atherosclerotic cardiovascular disease (ASCVD) is estimated using the American College of Cardiology (ACC)/American Heart Association (AHA) Pooled Cohort Equations (PCEs). However, the accuracy of this tool remains controversial, particularly among patients who are recommended statin therapy according to the ACC/AHA guidelines. We performed external validation of PCEs among patients eligible for statin therapy using data from the systolic blood pressure intervention trial (SPRINT). Results Our study included 4057 patients from among the 9361 patients in SPRINT. The mean patient age was 64.5 years, and the median predicted 10-year risks of ASCVD were 17.2% and 12.3% for men and women, respectively. Over a median follow-up of 3.3 years, 133 primary events (including 23 cardiovascular deaths) were noted, whereas 304 events were predicted by the PCEs. The PCEs demonstrated poor calibration (Hosmer–Lemeshow test, p
- Published
- 2019
43. Influence of Nonalcoholic Fatty Liver Disease on Locally Advanced Breast Cancer: A Retrospective Cohort Study
- Author
-
Ai Yamaguchi, Marina Shimizu, Yuki Kataoka, Tomoe Taji, Hirofumi Suwa, Kazuna Kawabata, and Makoto Umeda
- Subjects
medicine.medical_specialty ,Anthracycline ,business.industry ,Hazard ratio ,Retrospective cohort study ,General Medicine ,Disease ,medicine.disease ,Gastroenterology ,Breast cancer ,Internal medicine ,Nonalcoholic fatty liver disease ,medicine ,Steatosis ,skin and connective tissue diseases ,business ,Cohort study - Abstract
Background: Nonalcoholic fatty liver disease (NAFLD) is associated with poor prognosis after radical breast cancer surgery. Locally advanced breast cancer (LABC) has a higher recurrence rate than early breast cancer does and requires multidisciplinary treatment including cardiotoxic and liver-metabolized anthracycline. The aim of the current study was to investigate the association between NAFLD and the prognosis and morbidity of patients with LABC. Patients and Methods: This single-center, retrospective, cohort study included patients with stage III breast cancer who underwent surgery between July 2015 and December 2018. Hepatic steatosis was defined as a ratio of liver-to-spleen attenuation (L/S) of Results: We analyzed 44 patients, including 6 with NAFLD. The median follow-up time was 852.5 days. On univariate and multivariate analyses, NAFLD was not significantly associated with RFS (hazard ratio [HR], 1.474; 95% confidence interval [CI], 0.324–6.706, and HR, 1.297; 95% CI, 0.263–6.399, respectively). Neither cardiovascular events nor secondary cancers were associated with NAFLD. Known prognostic factors of breast cancer—such as older age, high histological grade, and estrogen receptor negativity—were significantly associated with a shorter RFS. Conclusion: When treating patients with LABC, physicians and patients should not worry much about the prognostic impact of mild NAFLD. Highlights: This single-center, retrospective, cohort study investigated the association between nonalcoholic fatty liver disease (NAFLD) and the prognosis and morbidity of patients with locally advanced breast cancer (LABC). We found that mild NAFLD was not significantly associated with RFS and neither cardiovascular disease nor other cancers occurred. The results of the current study imply that mild NAFLD based on the criteria given by Iwasaki et al. is not a prognostic factor for LABC.
- Published
- 2021
44. A Case of Unresolving Pneumonia
- Author
-
Taro Shimizu, Yuki Kataoka, Shuhei Yamamoto, and Sawako Kaku Hosokawa
- Subjects
030203 arthritis & rheumatology ,Pediatrics ,medicine.medical_specialty ,medicine.diagnostic_test ,business.industry ,Interstitial lung disease ,Physical examination ,medicine.disease ,Rash ,030207 dermatology & venereal diseases ,03 medical and health sciences ,Pneumonia ,0302 clinical medicine ,Pharmacotherapy ,Internal Medicine ,medicine ,Prednisolone ,Geriatrics and Gerontology ,Respiratory system ,medicine.symptom ,Family Practice ,business ,Myositis ,medicine.drug - Abstract
A 33-year-old woman was transferred to our hospital for an unresolving pneumonia, who initially presented with dyspnea. Initially antibiotic therapy was started under the suspicion of community-acquired pneumonia, however, her respiratory status worsened at the previous hospital. Computed tomography (CT) on presentation showed peripheral ground glass opacities in both sides of the upper lobe. Also despite additional prednisolone therapy, her respiratory status worsened. On admission to our hospital, physical examination showed Gottoron's sign in her right elbow. From the nature of the rash, the absence of myositis symptoms and rapid respiratory worsening, we suspected clinically amyopathic dermatomyositis (CADM). After the triple drug therapy, her respiratory status improved.
- Published
- 2016
45. The impact of antibiotics on the metabolic status of obese adults without bacterial infection: a systematic review and meta-analysis
- Author
-
Yasushi Tsujimoto, Shunsuke Taito, Yoshihiro Saito, Masahiro Banno, Yuki Kataoka, Ken-ichi Hirata, Tomoya Yamashita, and Naofumi Yoshida
- Subjects
medicine.medical_specialty ,biology ,medicine.drug_class ,business.industry ,Antibiotics ,General Medicine ,Gut flora ,Overweight ,biology.organism_classification ,medicine.disease ,Placebo ,Gastroenterology ,Obesity ,antibiotics ,meta-analysis ,Diarrhea ,Insulin resistance ,systematic review ,Internal medicine ,medicine ,Original Article ,medicine.symptom ,Adverse effect ,business - Abstract
BACKGROUND: The gut microbiota is involved in the pathophysiology of obesity. It is known that oral antibiotics manipulate the gut microbiota; however, the impact on host metabolism of obese adults without bacterial infection has not been systematically summarized. METHODS: We searched for randomized, placebo-controlled trials that investigated the effects of oral antibiotics on the metabolic status in obese adults via Medline, EMBASE, and the Cochrane Library. Primary outcomes were homeostasis model assessment of insulin resistance (HOMA-IR), body weight, and rate of diarrhea. Additional outcomes included fasting plasma glucose (FPG), plasma glucagon-like peptide-1 (GLP-1), waist circumference, fecal short-chain fatty acid (SCFA) levels, and all adverse events. We assessed the certainty of evidence based on Grading of Recommendations, Assessment, Development and Evaluations. RESULTS: Among 1,762 articles screened, four studies were eligible for quantitative analysis, two of which were applied to meta-analysis. Oral antibiotics had low influence on HOMA-IR [mean difference (MD) 0.09 (95% CI: −0.96 to 1.13)], body weight [MD 4.1 kg (95% CI: −23.77 to 31.97)], FPG [MD −0.12 mmol/L (95% CI: −0.47 to 0.23)], and GLP-1 [MD 0.20 pmol/L (95% CI: −2.36 to 2.76)] compared to placebo. Antibiotics treatment altered fecal acetate and butyrate levels, but resulted in little difference in propionate levels [MD −13.60 µmol/g (95% CI: −22.43 to −4.77), MD −7.60 µmol/g (−10.97 to −4.23), MD −1.10 µmol/g (95% CI: −4.18 to 1.98), respectively]. Several adverse events, such as sun sensitivity and gastrointestinal discomfort, were reported following antibiotics treatment, but no diarrhea. The certainty of evidence for most outcomes was very low to low, except for fecal SCFAs. CONCLUSIONS: Our results indicate that oral antibiotics treatment is insufficient to ameliorate metabolic parameters in obese adults, suggesting that oral antibiotics treatment may not qualify as a therapeutic approach for obesity.
- Published
- 2020
46. Corrigendum to 'External validation of prognostic indices for overall survival of malignant pleural mesothelioma' [Lung Cancer 113 (November) (2017) 88–92]
- Author
-
Shingo Fukuma, Sawako Kaku, Shunichi Fukuhara, Masataka Hirabayashi, Yosuke Yamamoto, Taiichiro Otsuki, Yuki Kataoka, Takashi Nakano, and Nobuko Maehashi-Wada
- Subjects
Pulmonary and Respiratory Medicine ,Oncology ,Cancer Research ,medicine.medical_specialty ,business.industry ,Pleural mesothelioma ,External validation ,medicine.disease ,Text mining ,Internal medicine ,Overall survival ,medicine ,business ,Lung cancer - Published
- 2020
47. Pseudoprogression in Previously Treated Patients with Non-Small Cell Lung Cancer Who Received Nivolumab Monotherapy
- Author
-
Tae Hata, Satoshi Hara, Yuki Kataoka, Mitsunori Morita, Toyohiro Hirai, Takehiro Yasuda, Keisuke Tomii, Moon Hee Hwang, Hitoshi Nakaji, Motonari Fukui, Young Hak Kim, Naoki Sakai, Masataka Hirabayashi, Tadashi Mio, Manabu Ishitoko, Hiroshige Yoshioka, Takakazu Sugita, Takeshi Morimoto, Yasushi Fukuda, Daichi Fujimoto, and Tadashi Ishida
- Subjects
0301 basic medicine ,Pulmonary and Respiratory Medicine ,Oncology ,Male ,medicine.medical_specialty ,Lung Neoplasms ,Adenocarcinoma of Lung ,03 medical and health sciences ,0302 clinical medicine ,Antineoplastic Agents, Immunological ,Internal medicine ,Carcinoma, Non-Small-Cell Lung ,medicine ,Humans ,In patient ,Lung cancer ,Pseudoprogression ,Aged ,Retrospective Studies ,business.industry ,Retrospective cohort study ,Middle Aged ,medicine.disease ,Prognosis ,Survival Rate ,030104 developmental biology ,Nivolumab ,030220 oncology & carcinogenesis ,Carcinoma, Squamous Cell ,Disease Progression ,Female ,Non small cell ,Previously treated ,business ,Progressive disease ,Follow-Up Studies - Abstract
Nivolumab is effective in the treatment of previously treated patients with advanced NSCLC. However, its radiological evaluation is challenging because of atypical patterns of response such as pseudoprogression. We examined the characteristics and outcomes of previously treated patients with NSCLC who were treated with nivolumab and experienced development of pseudoprogression.We conducted a 15-center retrospective cohort study of previously treated patients with advanced NSCLC who received nivolumab monotherapy. For the patients who showed pseudoprogression, we defined progression-free survival 1 (PFS1) as the time to Response Evaluation Criteria in Solid Tumors-defined first progressive disease and progression-free survival 2 (PFS2) as the time to Response Evaluation Criteria in Solid Tumors-defined second progressive disease or death.Among the 542 patients included, 20% and 53% showed a typical response and progression, respectively. Of the 14 (3%) patients who showed pseudoprogression, most (n = 10) showed a response within 3 months of nivolumab treatment. The median PFS1 and PFS2 were 1.0 and 7.3 months, respectively. The median PFS2 was significantly shorter in the patients who showed pseudoprogression than the PFS of the patients with a typical response (p 0.001). In contrast, patients showing pseudoprogression had significantly longer overall survival than did patients showing typical progression (p = 0.001).Pseudoprogression was uncommon, and the duration of response in patients who showed pseudoprogression was shorter than that in patients who showed a typical response. However, the survival benefit of pseudoprogression was markedly better than that of typical progression. Further research is required to elucidate the characteristics of and mechanisms underlying pseudoprogression.
- Published
- 2018
48. Diagnostic accuracy of specific IgG antibodies for bird fancier’s lung: a systematic review and meta-analysis
- Author
-
Yu Tanaka, Akihiro Shiroshita, Yuki Kataoka, Kei Nakashima, and Yuki Furukawa
- Subjects
medicine.medical_specialty ,Receiver operating characteristic ,biology ,business.industry ,General Medicine ,Cochrane Library ,medicine.disease ,Ouchterlony double immunodiffusion ,Confidence interval ,Immunoglobulin G ,Serology ,03 medical and health sciences ,0302 clinical medicine ,Bird fancier's lung ,030228 respiratory system ,Internal medicine ,Meta-analysis ,medicine ,biology.protein ,Original Article ,030212 general & internal medicine ,business - Abstract
Background: Serologic assays for specific immunoglobulin G (IgG) antibodies are available for diagnosing the condition of bird fancier’s lung, however, their usefulness is controversial. This systematic review was aimed at investigating the diagnostic accuracy of specific IgG antibodies used for avian antigens. Methods: Medline, Embase, the Cochrane Library, the International Clinical Trials Registry Platform, and the Web of Science were searched for studies performed to evaluate the diagnostic accuracy of the Ouchterlony method, enzyme-linked immunosorbent assays (ELISAs), electrosyneresis, and ImmunoCAP assays for diagnosing bird fancier’s lung. Nine articles were included in the meta-analysis. The pooled sensitivity and specificity were summarized using a bivariate mixed-effects model, and a hierarchical summary receiver operating characteristic curve was rendered to determine the diagnostic accuracy of the antibodies. Results: The pooled sensitivities and specificities of each specific IgG antibody were 82.9% (95% confidence interval, 71.1–90.5%) and 93.0% (95% confidence interval, 74.4–98.4%) for the Ouchterlony method, 92.5% (95% confidence interval, 71.3–98.4%) and 90.8% (95% confidence interval, 72.1–97.4%) for ELISAs, 90.0% (95% confidence interval, 55.5–99.7%) and 84.6% (95% confidence interval, 73.5–92.4%) for the electrosyneresis method, and 43.5% (95% confidence interval, 35.3–52.1%) and 100% (95% confidence interval, 0–100%) for ImmunoCAP assays. The overall quality of the collective evidence was low, primarily due to the high risk of bias, indirectness, and imprecision of the included studies. Conclusions: The Ouchterlony method demonstrated high specificity, the ELISA method showed high sensitivity, and the diagnostic utilities of electrosyneresis and ImmunoCAP assay testing remain unclear.
- Published
- 2019
49. Third-line systemic chemotherapy for small cell lung cancer
- Author
-
Morihiro Katsura, Katsuya Hirano, Yuki Kataoka, Hiraku Tsujimoto, Hirotaka Matsumoto, Shunkichi Ikegaki, and Yukihiko Nakata
- Subjects
Medicine General & Introductory Medical Sciences ,Oncology ,medicine.medical_specialty ,business.industry ,Systemic chemotherapy ,education ,respiratory tract diseases ,03 medical and health sciences ,0302 clinical medicine ,Text mining ,Third line ,030220 oncology & carcinogenesis ,Internal medicine ,medicine ,Pharmacology (medical) ,030212 general & internal medicine ,Non small cell ,business - Abstract
This is a protocol for a Cochrane Review (Intervention). The objectives are as follows: To assess the effectiveness and safety of third‐line chemotherapy in patients with small cell lung cancer (SCLC), compared to conventional supportive care.
- Published
- 2018
50. Prognostic Impact of Inflammation-related Biomarkers on Overall Survival of Patients with Inoperable Malignant Pleural Mesothelioma
- Author
-
Yuki Kataoka, Masataka Hirabayashi, Reika Iki, Takehiro Otoshi, and Sawako Kaku
- Subjects
Male ,Mesothelioma ,0301 basic medicine ,Oncology ,Cancer Research ,medicine.medical_specialty ,Lung Neoplasms ,Multivariate analysis ,Neutrophils ,Pleural Neoplasms ,Inflammation ,Kaplan-Meier Estimate ,General Biochemistry, Genetics and Molecular Biology ,Leukocyte Count ,03 medical and health sciences ,0302 clinical medicine ,Internal medicine ,Overall survival ,medicine ,Humans ,Lymphocytes ,Neutrophil to lymphocyte ratio ,Serum Albumin ,Aged ,Neoplasm Staging ,Retrospective Studies ,Aged, 80 and over ,Pharmacology ,business.industry ,Proportional hazards model ,Medical record ,Mesothelioma, Malignant ,Hazard ratio ,Middle Aged ,Prognosis ,Combined Modality Therapy ,Confidence interval ,C-Reactive Protein ,030104 developmental biology ,030220 oncology & carcinogenesis ,Female ,Inflammation Mediators ,medicine.symptom ,business ,Biomarkers ,Research Article - Abstract
Aim The aim of the present study was to assess the prognostic utility of the pretreatment blood neutrophil-to-lymphocyte ratio (NLR) and the C-reactive protein-to-albumin ratio (CAR) in patients with inoperable malignant pleural mesothelioma (MPM). Materials and methods The medical records of consecutive patients with histologically confirmed MPM from our hospital between January 2007 and August 2017 were retrospectively reviewed. The primary outcome was overall survival (OS). Univariate and multivariate analyses for the prognostic factors were performed using a Cox proportional hazards model. Results A total of 143 patients with inoperable MPM were included. On multivariate analysis, pretreatment CAR was an independent factor associated with worse OS (hazard ratio(HR)=1.72; 95% confidence interval(CI)=1.11-2.67; p=0.016). However, NLR was not associated with OS in any of the analyses. Conclusion CAR appears to be a prognostic factor in patients with inoperable MPM.
- Published
- 2018
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.